US20010053769A1 - Use of pro-apoptotic factors in treatment of atherosclerosis - Google Patents
Use of pro-apoptotic factors in treatment of atherosclerosis Download PDFInfo
- Publication number
- US20010053769A1 US20010053769A1 US09/765,519 US76551901A US2001053769A1 US 20010053769 A1 US20010053769 A1 US 20010053769A1 US 76551901 A US76551901 A US 76551901A US 2001053769 A1 US2001053769 A1 US 2001053769A1
- Authority
- US
- United States
- Prior art keywords
- smooth muscle
- organ
- muscle cell
- cells
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000001320 Atherosclerosis Diseases 0.000 title claims description 50
- 230000000861 pro-apoptotic effect Effects 0.000 title abstract description 37
- 238000011282 treatment Methods 0.000 title description 29
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims abstract description 347
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 159
- 210000000056 organ Anatomy 0.000 claims abstract description 112
- 238000000034 method Methods 0.000 claims abstract description 111
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 94
- 208000019553 vascular disease Diseases 0.000 claims abstract description 46
- 210000004027 cell Anatomy 0.000 claims description 112
- 230000014509 gene expression Effects 0.000 claims description 86
- 230000006907 apoptotic process Effects 0.000 claims description 82
- 239000003814 drug Substances 0.000 claims description 51
- 210000001519 tissue Anatomy 0.000 claims description 49
- 230000035755 proliferation Effects 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 37
- 229940124597 therapeutic agent Drugs 0.000 claims description 34
- 102000004127 Cytokines Human genes 0.000 claims description 33
- 108090000695 Cytokines Proteins 0.000 claims description 33
- 108020004414 DNA Proteins 0.000 claims description 33
- 230000001965 increasing effect Effects 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 28
- 230000004054 inflammatory process Effects 0.000 claims description 25
- 206010061218 Inflammation Diseases 0.000 claims description 24
- 208000014674 injury Diseases 0.000 claims description 23
- 230000004913 activation Effects 0.000 claims description 22
- 241000894007 species Species 0.000 claims description 22
- 238000002054 transplantation Methods 0.000 claims description 22
- 230000004071 biological effect Effects 0.000 claims description 20
- 230000009261 transgenic effect Effects 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 20
- 208000027418 Wounds and injury Diseases 0.000 claims description 19
- 230000006378 damage Effects 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 15
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims description 14
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 12
- 210000002216 heart Anatomy 0.000 claims description 12
- 230000003213 activating effect Effects 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 238000002399 angioplasty Methods 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- 230000002792 vascular Effects 0.000 claims description 10
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 208000034827 Neointima Diseases 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 102000040945 Transcription factor Human genes 0.000 claims description 7
- 108091023040 Transcription factor Proteins 0.000 claims description 7
- 230000000392 somatic effect Effects 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 230000004957 immunoregulator effect Effects 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000000144 pharmacologic effect Effects 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 3
- 230000030833 cell death Effects 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 abstract description 23
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 22
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 11
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 11
- 235000018102 proteins Nutrition 0.000 description 78
- 210000002889 endothelial cell Anatomy 0.000 description 48
- 108010057466 NF-kappa B Proteins 0.000 description 42
- 102000003945 NF-kappa B Human genes 0.000 description 42
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 41
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 41
- 230000001404 mediated effect Effects 0.000 description 41
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 33
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 20
- 101150064015 FAS gene Proteins 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 20
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 20
- 230000004044 response Effects 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 238000012546 transfer Methods 0.000 description 16
- 230000022131 cell cycle Effects 0.000 description 15
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 230000002018 overexpression Effects 0.000 description 15
- 230000002424 anti-apoptotic effect Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 230000003827 upregulation Effects 0.000 description 13
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000001640 apoptogenic effect Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 9
- 239000004098 Tetracycline Substances 0.000 description 9
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 229930101283 tetracycline Natural products 0.000 description 9
- 229960002180 tetracycline Drugs 0.000 description 9
- 235000019364 tetracycline Nutrition 0.000 description 9
- 150000003522 tetracyclines Chemical class 0.000 description 9
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 101150013553 CD40 gene Proteins 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 7
- 230000012173 estrus Effects 0.000 description 7
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 241000282887 Suidae Species 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000003101 oviduct Anatomy 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 230000026799 smooth muscle cell apoptotic process Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000489 anti-atherogenic effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000002633 protecting effect Effects 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 230000004668 G2/M phase Effects 0.000 description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
- 101000830570 Homo sapiens Tumor necrosis factor alpha-induced protein 3 Proteins 0.000 description 4
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- -1 adhesion molecules Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 231100000216 vascular lesion Toxicity 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- 206010016825 Flushing Diseases 0.000 description 3
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 102000045235 human TNFAIP3 Human genes 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000006461 physiological response Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 101100095984 Caenorhabditis elegans smc-4 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 230000035519 G0 Phase Effects 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 206010038997 Retroviral infections Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000008889 TNF receptor-associated factor TRAF Human genes 0.000 description 2
- 108050000808 TNF receptor-associated factor TRAF Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 201000010235 heart cancer Diseases 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000024348 heart neoplasm Diseases 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 210000000472 morula Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000008692 neointimal formation Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000000207 pro-atherogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000007631 vascular surgery Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- VWAUPFMBXBWEQY-ANULTFPQSA-N Altrenogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC=C)C=C3)C3=C21 VWAUPFMBXBWEQY-ANULTFPQSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 101150086009 CRIP2 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010069621 Epstein-Barr virus EBV-associated membrane antigen Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 101100439107 Rattus norvegicus Cebpb gene Proteins 0.000 description 1
- 101100054071 Rattus norvegicus Crp2 gene Proteins 0.000 description 1
- 101100275975 Rattus norvegicus Csrp2 gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010073007 Septic vasculitis Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 102000046768 human CCL2 Human genes 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008069 intimal proliferation Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229940090213 lutalyse Drugs 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006715 negative regulation of smooth muscle cell proliferation Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108010038751 tax Gene Products Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0661—Smooth muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to the field of vascular disease.
- Vascular disease is the most common cause of morbidity and mortality in the western world, surpassing any other single degenerative disease.
- the fundamental pathology of vascular disease is an abnormal accumulation of cells within the subintimal space below the surface of the endothelial cell lining, resulting in a decrease in lumen size and tissue perfusion. This accumulation is due to the proliferation and/or migration of smooth muscle cells, and/or inflammatory cells into the intimal layer of a vessel, resulting in restricted blood flow through that vessel, i.e. neointimal occlusive lesions.
- lipid-lowering agents e.g., for treatment of atherosclerosis
- immunosuppressive regimens are used in the treatment of atherosclerosis.
- TAV transplant-associated vasculopathy
- TAV is closely related to atherosclerosis and remains the major barrier to successful transplantation (Brooks-Wilson et al., Nature Genetics, (1999) 22:327-335; Kirk et al., Nature Medicine (1999) pages 686-693; Hancock et al., Nature Medicine, (1998) 4:1392-1396).
- surgical strategies have been developed that are aimed at bypassing the obstruction with venous conduits, or stretching the vessel to create a larger lumen by performing balloon angioplasty.
- the present invention is based on the finding that A20 is a pro-apoptotic factor in smooth muscle cells, a finding which would not have been predicted based on the anti-apoptotic role previously established for A20 in endothelial cells.
- the present invention thus provides therapeutic strategies for up-regulating pro-apoptotic factors in smooth muscle cells for prevention and treatment of vascular disease.
- the present invention provides a method of treating vascular disease by (1) modifying mammalian smooth muscle cells so that they exhibit increased anti-inflammatory and pro-apoptotic activity, and (2) transplanting the smooth muscle cells into a transplant candidate or a patient diagnosed with a vascular disease (e.g., atherosclerosis, transplant-associated vasculopathy, or chronic rejection).
- a vascular disease e.g., atherosclerosis, transplant-associated vasculopathy, or chronic rejection.
- the smooth muscle cells are selectively treated.
- the present invention is useful in the treatment and prevention of atherosclerosis and transplant-associated vasculopathy (TAV).
- TAV transplant-associated vasculopathy
- the increase in anti-inflammatory and pro-apoptotic activity is accomplished by inserting into the smooth muscle cell, or a progenitor thereof, DNA encoding A20 capable of decreasing inflammation and increasing apoptosis of the smooth muscle cell.
- the A20 protein employed by the methods of the invention also achieves an anti-proliferative effect in the smooth muscle cell.
- the methods include introduction of nucleic acid to a tissue or organ having smooth muscle cells, such as a vessel, a heart, a kidney or a liver into smooth muscle cells.
- the method of the present invention can be applied to prevent TAV in a patient at risk for developing TAV.
- This method involves modifying a mammalian smooth muscle cell by inserting into the smooth muscle cell DNA encoding a protein capable of decreasing inflammation and increasing apoptosis of the smooth muscle cell and transplanting the smooth muscle cell (or tissue or organ having a smooth muscle cell) into the patient.
- a patient classified as a patient at risk for developing TAV would be, for example, a patient receiving an organ or vessel transplant.
- the anti-inflammatory/pro-apoptotic protein is preferably the A20 protein.
- the present invention is based on the discovery that the A20 protein, previously thought to be an anti-apoptotic factor, has pro-apoptotic activity in smooth muscle cells. Included in certain aspects of the invention is the use of mutants and derivatives of the A20 protein that may have increased activity or expression in smooth muscle cells.
- the invention provides a method of treating atherosclerosis, or preventing TAV by transplanting donor smooth muscle cells, or graftable tissues or organs having smooth muscle cells into a mammalian recipient diagnosed with atherosclerosis or at risk for developing TAV.
- the first step requires modifying the donor smooth muscle cells, or progenitor cells thereof, by inserting therein nucleic acid encoding the A20 protein.
- the second step requires transplanting the resultant modified donor smooth muscle cells, or tissue, or organ comprising the cells into the recipient and expressing in the cells the A20 protein, thereby substantially promoting apoptosis.
- smooth muscle cells modified by this procedure are capable of substantially inhibiting inflammation in the presence of a cellular activating stimulus (e.g., TNF).
- the present invention also provides a method of preparing a vascularized organ or vessel for transplantation into a patient by obtaining an organ or vessel for transplant and perfusing the organ with nucleic acid encoding the A20 protein.
- a variety of vectors are available in the art for gene transfer. Particularly preferred vectors are the adenovirus vector and the lentivirus vector.
- the organ or vessel is perfused with a gene transfer vector and an immunoregulatory factor (e.g., a cytokine).
- an immunoregulatory factor e.g., a cytokine
- a therapeutic agent may be perfused into the organ or vessel to enhance the expression of A20.
- Organ and vessel transfer procedures can be most effectively applied to patients that have suffered ischemia, reperfusion injury, mechanical injury, immunologic injury, pharmacologic injury, or coronary trauma.
- methods of organ and vessel transfer can be applied to a patient who has undergone balloon angioplasty.
- the most preferred application of the organ or vessel transfer procedure of the present invention is in the treatment of patients diagnosed with atherosclerosis.
- the organ or vessel being prepared is a vascularized organ transplant or a vascular graft.
- the present invention also relates to a mammalian smooth muscle cell that is modified to express the A20 protein.
- Expression of the A20 protein imparts on the smooth muscle cell an anti-inflammatory/pro-apoptotic effect in the presence of a cellular activating stimulus.
- the modified smooth muscle cell thereby exhibits increased apoptosis, relative to an untreated smooth muscle cell.
- the A20 protein also blocks smooth muscle cell proliferation.
- the present invention also relates to a donor smooth muscle cell, or a tissue or organ having a smooth muscle cell, for transplantation into a recipient species, wherein the cell is modified to express A20.
- a therapeutic agent may applied to the cell to enhance the expression of A20.
- the invention provides an organ or vessel from a non-human transgenic or somatic recombinant mammal comprising DNA encoding a pro-apoptotic protein of a different species.
- the non-human transgenic or recombinant mammal thus acts as a stable source of transplant tissue.
- the non-human animal is porcine and the pro-apoptotic factor is human.
- the present invention also provides a method of identifying compounds that substantially promote apoptosis and substantially inhibit growth or proliferation in smooth muscle cells.
- the method requires exposing smooth muscle cells to a test compound and assaying the smooth muscle cells for increased apoptosis and reduced growth or proliferation.
- a variety of methods are available for assaying increased apoptosis and reduced growth or proliferation.
- assays that measure A20 biological activity in smooth muscle cells i.e., the ability to promote apoptosis and inhibit proliferation
- these assays represent methods of detecting binding of a compound to a pro-apoptotic protein of interest (i.e., A20).
- Particularly preferred compounds include compounds that enhance A20 biological activity or increase the level of A20 in a smooth muscle cell.
- the present invention also provides a method of treating a patient having a vascularized organ transplant, a vessel transplant, or vascular disease by enhancing A20 biological activity.
- Therapeutic agents such as the compounds identified as described above, that enhance A20 biological activity, can be used to treat patients having vascularized organ transplants, vessel transplants, or vascular diseases.
- Such compounds can also be applied to the prevention of vascular disease in a patient.
- Such compounds are preferably in the form of a therapeutic agent, e.g., a cytokine, Fas, or a drug.
- a mutant A20 gene might be employed that encodes an A20 protein that exhibits increased A20 biological activity.
- the present invention also relates to a method of promoting apoptosis in smooth muscle cells in a patient, by increasing the level of A20 in the smooth muscle cells.
- One mechanism of achieving this goal is to modify smooth muscle cells to express A20.
- Another mechanism by which to achieve increased A20 expression in a smooth muscle cell is to employ a mutant of the A20 gene encoding a protein that is expressed at a higher level in A20 cells.
- Yet another mechanism by which the level of A20 protein can be increased in a smooth muscle cell is by administration of a therapeutic agent to the smooth muscle cell, (e.g., a cytokine, a transcription factor, Fas, or a drug).
- a therapeutic agent e.g., a cytokine, a transcription factor, Fas, or a drug.
- the method is used to treat a patient with a vascularized organ transplant, a vessel transplant or vascular disease (e.g., TAV, or atherosclerosis).
- Vascular disease is used herein to refer to atherosclerosis, transplant-associated vasculopathy, chronic rejection, stenosis (e.g., vein graft stenosis or peri-anastomatic prosthetic graft stenosis), restenosis (e.g., restenosis after angioplasty or stent placement, and the like), human atheroma, septic shock, and vasculitis.
- vascular disease also refers to vascular conditions that develop after a surgical treatments, such as, venous bypass surgery, balloon angioplasty, post-angioplasty of atherosclerotic plaques of both coronary and peripheral arteries, and allo- and xenograft rejection.
- vascular disease is used to refer to the disease of a patient that has suffered ischemia, reperfusion injury, mechanical injury, immunologic injury, pharmacologic injury of a vessel, or coronary trauma.
- the patient has undergone balloon angioplasty.
- A20 refers to a natural mammalian A20 gene, including the cDNA or protein thereof.
- A20 also include derivatives having variations in the cDNA (SEQ ID NO: 1) or amino acid (SEQ ID NO:2) sequence. Included in the definition of A20 are derivatives of the A20 protein having conserved amino acid substitutions.
- A20 includes mutants having alterations in one or more amino acids that either maintain or increase the activity of A20.
- the A20 gene or protein employed in the invention may, for example, be porcine, bovine, or primate (e.g., a human), depending on the nature of the cells to be modified and the intended recipient species for transplantation.
- A20 gene is meant a gene encoding a polypeptide having A20 pro-apoptotic/anti-inflammatory activity in smooth muscle cells or other biological activities described herein.
- An A20 gene is a gene encoding an A20 polypeptide having about 60% or greater, more preferably 70% or greater amino acid sequence identity to the A20 amino acid sequence of SEQ ID NO:2, or a portion thereof.
- the gene may encode human or murine A20 polypeptide.
- An A20 gene may also be defined as encoding a polypeptide with at least 50% of the activity of the A20 polypeptides described below.
- the A20 gene is a human or murine A20 gene.
- the A20 gene of the invention is at least 70%, and more preferably at least 80%, or at least 90% homologous to SEQ ID NO:1.
- a protein or polypeptide “having A20 activity” or “A20 active protein” refers to a protein which is able to block or suppress nuclear factor ⁇ B (NF- ⁇ B) activation, and which is at least 70%, preferably at least 80%, and more preferably at least 90% (most preferably at least 95%) homologous to the protein sequence of a natural mammalian A20 protein (e.g., human) (SEQ ID NO:2) (see, Dixit et al., J. Biol. Chem., (1990) 265:2973, and WO 05/0062, which are hereby incorporated by reference).
- NF- ⁇ B nuclear factor ⁇ B
- blocking is meant at least 50% inhibition of I ⁇ B degradation that occurs after TNF stimulation, but blocking can also mean a 50% or greater inhibition of NF ⁇ B binding to ⁇ B elements on the DNA, or a 50% or greater decrease in the up-regulation of mRNA seen for NF ⁇ B-regulated genes following TNF treatment, such genes include, for example, ICAM-1 and MCP-1.
- therapeutic gene is meant a DNA that achieves an anti-proliferative, pro-apoptotic effect in smooth muscle cells.
- the therapeutic gene may also have the effect of decreasing inflammation, (e.g., by inhibiting NF- ⁇ B activation in a smooth muscle cell).
- Inflammation refers to a cellular response to TNF that constitutes in part activation of NF- ⁇ B.
- An “anti-inflammatory” is a permeable factor (protein, peptide, or chemical agent (i.e., a drug)) that suppresses, inhibits or blocks the cellular response to TNF and NF- ⁇ B activation.
- “Host” or “recipient” refers to the body of the patient into whom donor biological material is grafted.
- the host is an animal which is of interest for experimental investigations, providing a model for treatment of human disease.
- the host is a mammal or patient, and may be any mammalian species.
- the mammalian host may be a rodent (e.g., including mice, rats and hamsters), or another mammal (e.g., rabbits, equines, bovines, canines, felines, etc.).
- rodent e.g., including mice, rats and hamsters
- Another mammal e.g., rabbits, equines, bovines, canines, felines, etc.
- Such mammals are of interest for the study of experimentally induced vascular lesions.
- a particularly preferred host is a primate.
- a most preferred mammalian host is a human.
- a “patient at risk” for developing TAV may include all patients receiving allo- or xenogeneic tissue or organ transplants.
- a “vascularized organ transplant,” according to the present invention includes any organ having vasculature and containing smooth muscle cells.
- the heart, liver, and kidney are vascularized organs that can be used for transplant according to the present invention.
- “Vascularized organ transplant,” as used herein, refers to any organ that may be used in a transplant procedure to replace a like organ that has suffered end-stage organ failure.
- “Graft,” “transplant”, or “implant” are used interchangeably to refer to biological material derived from a donor for transplantation into a recipient, and to the act of placing such biological material in the recipient.
- Allogeneic refers to the donor and recipient being of the same species (also, allograft). As a subset thereof, “syngeneic” refers to the condition wherein donor and recipient are genetically identical. “Autologous” refers to donor and recipient being the same individual. “Xenogeneic” (and “xenograft”) refer to the condition where the graft donor and recipient are of different species.
- constitutive when used in reference to a promoter is meant substantially continuous transcription of the gene and expression of the protein over the life of the cell.
- “regulable” when used in reference to a promoter is meant that the transcription of the gene and expression of the protein is related to the presence, or absence, of a given substance.
- An embodiment of “regulable” expression includes “inducible” expression, i.e. whereby transcription (and thus protein expression) occurs on demand in response to a stimulus.
- the stimulus may comprise activating stimuli or a predetermined external stimulus.
- the activating stimuli may be any of the stimuli which give rise to changes in the endothelium or smooth muscle cells of donor tissue or organs which contribute to vascular disease.
- the predetermined external stimulus may be the presence of a drug, cytokine, or other agent.
- An example of a drug stimulus is tetracycline, which has the ability to activate the tetracycline responsive promoter.
- the activating stimuli may be TNF mediated NF- ⁇ B activation.
- Candidate compound,” “test compound,” “agent,” or “therapeutic agent” as used herein include any molecule or permeable factor, e.g., a protein or pharmaceutical, i.e., a drug, with the capability of substantially promoting apoptosis and substantially inhibiting smooth muscle cell growth or proliferation.
- A20 biological activity is meant, the ability of A20 to decrease inflammation and increase apoptosis in smooth muscle cells.
- A20 biological activity also includes the ability to decrease proliferation of smooth muscle cells.
- assays are described herein (see, Examples) that measure A20 biological activity.
- enhanced biological activity as used herein in reference to the A20 protein, is meant, that the pro-apoptotic/anti-proliferative activity of the A20 protein has been increased above that of the wild-type A20 protein.
- the A20 protein is present in a greater quantity or has greater biological activity in a modified smooth muscle cell compared to the level of A20 protein in an unmodified wild-type smooth muscle cell.
- FIG. 1 is a photograph of a Western blot depicting A20 expression induction by TNF (panel A) and a photograph of immunohistochemical analysis of A20 expression in smooth muscle cells after TNF treatment (panel B).
- FIG. 2 is a photograph of an electrophoretic mobility shift assay (EMSA) depicting inhibition of NF- ⁇ B binding to DNA upon A20 expression (panel A) and a photograph of a Western blot depicting inhibition of I ⁇ B ⁇ degradation in the presence of A20 (panel B).
- ESA electrophoretic mobility shift assay
- FIG. 3 is a photograph of a Northern blot depicting inhibition of ICAM-1 up regulation by A20.
- FIG. 4 is a graph depicting inhibition of smooth muscle cell proliferation by A20.
- FIG. 5 is a graph depicting A20-induced apoptosis of smooth muscle cells in response to cytokine treatment.
- FIG. 6 is a photograph of immunohistochemical analysis of A20 expression in heart vessels of control and transgenic mice.
- FIG. 7 is a photograph of a Northern blot showing that overexpression of A20 in SMC inhibits TNF-mediated up-regulation of MCP-1 mRNA as compared to not infected (NI) and rAd. ⁇ -gal-infected cells.
- FIG. 8 depicts the percent of not infected (NI), rAd.A20 infected, or rAd. ⁇ -gal infected cells undergoing apoptosis in response to various treatments.
- FIG. 9 is a photograph of a Northern blot showing that overexpression of A20 in SMC inhibits ⁇ Fas-mediated up-regulation of MCP-1 mRNA and also down-regulates the constitutive level detected in not infected (NI) cells.
- FIG. 10 is a photograph of a Western blot indicating that expression of A20 in SMC does not modify constitutive levels of Bcl-2 or Bcl-x L expression, nor their levels upon addition of cytokines.
- the present invention provides an alternative approach to inhibiting atherosclerosis through modifying cells in the vessel wall, particularly smooth muscle cells, that appear to be involved in the development of lesions associated with vascular disease, particularly atherosclerosis and TAV.
- This approach may offer the advantage of protecting against atherosclerosis and TAV regardless of the factors responsible for their initiation.
- a “therapeutic gene” encoding and expressing a therapeutic protein achieves an anti-inflammatory, pro-apoptotic effect in smooth muscle cells (SMC).
- the therapeutic gene also achieves an anti-proliferative effect in smooth muscle cells.
- the therapeutic gene also achieves an anti-inflammatory effect in endothelial cells (EC).
- Atherosclerosis may be viewed as a chronic inflammatory response to high concentrations of oxidized LDL (Steinberg, Nutrition and Biotechnology in Heart Disease and Cancer, 1995 pages 39-48; Ross, N. Engl. J Med., (1986) 314:488-500). This response consists of a series of cellular and biochemical events.
- the present invention is based on the concept that mediators released by cells in the lesion may contribute to the development of atherosclerosis.
- SMC contribute to the atherosclerotic lesion by essentially three mechanisms: (i) promotion of inflammation, (ii) aberrant SMC proliferation and migration within the neointima, and (iii) dysregulated SMC apoptosis (Ross, supra, Pomerantz et al., Nutrition and Biotechnology in Heart Disease and Cancer 1995 page 4964; Rekhter et al., Am. J. Pathol. (1995) 147:668-667; Bennett, Cardiovasc. Res.
- EC cells contribute to the development of the atherosclerotic lesion by acquiring an inflammatory phenotype that promotes leukocyte infiltration, macrophage infiltration, coagulation and platelet aggregation. EC cell activation further leads to thrombosis and ischemia, foam cell development, matrix deposition, as well as promotion of SMC migration and proliferation in the neointima (Cotran et al., J Am. Soc. Nephrol. (1990) 1:225-235; Gimbrone, American Journal of Cardiology (1995) 75:67B-70B).
- Transplant-associated vasculopathy is the main feature of chronic allograft rejection.
- TAV is a form of accelerated atherosclerosis resulting from a chronic inflammatory process initiated by the immune response to the allograft (Tullius et al., Transplantation (1995) 59:2126-2128; Ardehali et al., Circulation (1995) 92:450-456).
- Pathologically with the exception of foam cell development, the lesions of TAV are quite similar to those of the atherosclerotic plaque.
- the present invention provides insight into the pathogenesis of these related diseases and the regulatory processes which maintain the structure and homeostatic functions of a healthy vessel. Through this understanding, a strategy for protecting vessels from atherosclerosis and TAV is proposed.
- A20 is a zinc finger protein originally identified as a tumor necrosis factor (TNF)-inducible gene in human umbilical vein endothelial cells (HUVEC) (Opipari et al., J. Biol. Chem. (1990) 265:14705-14708).
- A20 is expressed in a variety of cell types in response to a number of stimuli such as interleukin (IL)-1 in HUVEC, CD40 cross-linking in B cells, phorbol 12-myristate 13-acetate (PMA) or HTLVI Tax protein in Jurkat T cells, Epstein Barr Virus latent membrane protein-1 and lipopolysaccharide (LPS) (Tewari et al., J.
- IL interleukin
- PMA phorbol 12-myristate 13-acetate
- LPS lipopolysaccharide
- apoptosis is characterized by loss of contact with neighboring cells, concentration of cytoplasm, endonuclease activity-associated chromatin condensation, pyknosis, and segmentation of the nucleus. Disappearance of microvilli from the cell surface and vesicle formation on the cell surface (membrane blebbing) are also observed. The remaining fragments of apoptotic body cells are phagocytosed by neighboring cells (see, Duvall, E. and Wyllie, A. H., Immunology Today (1986) 7(4):115-119).
- apoptotic cell death is considered to be of fundamental importance in inflammation, embryogenesis, and lymphocyte selection. Avoidance of cell activation and apoptotic cell death accompanying inflammation, particularly in connection with organ transplantation, has become a major goal for researchers in the art.
- endothelial cells graft injury and loss occurring in connection with graft preservation techniques and accompanying graft rejection exemplify the need for prevention of such a process.
- the present invention is based on the premise that promotion of apoptosis may actually be desirable for graft preservation and prevention of atherosclerosis and TAV in certain cell types, including smooth muscle cells.
- the deduced sequence of 790 amino acids contains within its carboxyl terminal half 7 Cys 2 /Cys 2 zinc finger repeats; six with the configuration Cys-X 4 -Cys-X 11 -Cys-X 2 -Cys and one with the configuration Cys-X 2 -Cys-X 11 -Cys-X 2 -Cys, wherein X is any amino acid and the subscripts represent numbers of amino acids between each of the indicated cysteines.
- the zinc finger repeat region is important for activity of A20 in endothelial and other cell types.
- a novel finger loop domain composed of 11 amino acid residues has also been identified (see Opipari et al., supra).
- the protein having A20 activity comprises amino acid residues 386-790 of SEQ ID NO:2, comprising the zinc finger region of the native protein sequence, or a region at least 80% homologous to the residues.
- Another suitable truncated form of the native human protein consists essentially of residues 373-790 of SEQ ID NO:2.
- mutants useful to the invention may include the zinc finger region of the protein but are not exclusive to the zinc finger region of the protein (see, Natoli et al. J. Biol. Chem. (1998) 273:31262-31272). The mutants may be identified by introducing specific desired mutations into a particular region of the A20 gene and testing the resultant mutant protein for a desired activity.
- A20 has a dual “cytoprotective” role in EC because it is both anti-apoptotic and anti-inflammatory.
- A20 is expressed in EC and SMC of long term surviving hamster to rat heart xenografts and is associated with the absence of inflammation, apoptosis, and of TAV in long term surviving hamster to rat xenograft (Bach et al., Nature Medicine (1997) 3:196-204). It has been demonstrated that the anti-inflammatory effect of A20 is mediated via blockade of the transcription factor NF- ⁇ B (see Grilli et al., International Review of Cytology, (1993) 13:1-61).
- NF- ⁇ B is a transcriptional activator associated with immediate early gene expression in EC activation.
- NF- ⁇ B is usually sequestered in the cytoplasm in association with its inhibitor I ⁇ B ⁇ (Baldwin, Ann. Rev. Immunol. (1996) 14:649-681).
- I ⁇ B ⁇ is phosphorylated, ubiquitinated and subsequently degraded in the proteasome allowing translocation of NF- ⁇ B to the nucleus of the EC (Traenckner et al., EMBO J. (1994) 13:5433-5441; Traenckner et al., J. Cell Sci.
- A20 belongs to a sub-set of TNF-inducible genes which assist in ultimately conferring resistance to TNF-induced apoptosis in EC (see, Tewari et al., J. Immunol. (1995) 1699-1706; Ferran et al., Blood (1998) 91:2249-2258; Opipari et al., J. Biol. Chem. (1990) 285: 14705-14708; Dixit et al., J. Biol. Chem. (1990) 264, 16905-16909).
- TNF induces expression of A20 in EC, through NF- ⁇ B binding sites located in the A20 promoter, extending from ⁇ 45 to ⁇ 54 (5′-GGAAATCCCC-3′) (SEQ ID NO:3) and from ⁇ 57 to ⁇ 66 (5′-GGAAAGTCCC-3′) (SEQ ID NO:4) of the A20 gene (Laherty et al., J. Biol. Chem. (1993,)268, 5032-5039; Krikos et. al., J. Biol. Chem. (1992) 267:17971-17976).
- NF- ⁇ B may drive the cell cycle through induction of cyclin D1, in the mid-G1 phase of the cell cycle (Hinz et al., Mol. Cell. Biol. (1999) 19:2690-2698; Sherr et al., Cell. (1993) 73:1059-1065; Roberts, Cell (1999) 98:129-132).
- Inhibition of the cell cycle in SMC inhibits SMC proliferation and has been demonstrated to redirect the vascular disease response away from neointimal hyperplasia and toward medial hypertrophy (Mann et al., Proc. Natl.
- blockade of NF- ⁇ B would also serve an anti-inflammatory function by inhibiting the up-regulation of NF- ⁇ B dependent genes that are deleterious for the development of atherosclerosis (e.g., adhesion molecules ICAM-1 and VCAM-1, pro-inflammatory receptors CD40 and CD40L, growth factors, and matrix proteinases) (Ross et a., supra; Ardehali et al., supra; Mach et al., Nature (1998) 394:200-203).
- atherosclerosis e.g., adhesion molecules ICAM-1 and VCAM-1, pro-inflammatory receptors CD40 and CD40L, growth factors, and matrix proteinases
- A20 provides a critical pathophysiological basis of a variety of conditions, including allo- and xenograft rejection, vasculitis and atherosclerosis.
- U.S. Ser. No. 08/601,515 filed Feb. 14, 1996, incorporated herein by reference, discloses the use of gene therapy techniques utilizing A20 and other anti-apoptotic/anti-inflammatory genes and their expression products to prevent and treat inflammation in endothelial cells.
- the present invention provides therapeutic strategies directed at up-regulating pro-apoptotic factors (or down-regulating anti-apoptotic factors) for inhibition of vascular lesion formation and prevention or treatment of vascular disease.
- the protective gene should achieve an anti-proliferative and pro-apoptotic effect in SMC.
- protection of SMCs in the vessel wall that appear to underlie the development of lesions associated with atherosclerosis, TAV, and other vascular diseases can be achieved by modifying the SMC so that it expresses a pro-apoptotic factor.
- A20 is expressed in SMC in response to TNF (a pro-inflammatory stimulus), establishing that A20 expression as part of the physiological response of SMC to injury (see, Example 1).
- TNF a pro-inflammatory stimulus
- overexpression of A20 in SMC inhibits NF- ⁇ B activation in response to TNF (see, Example 1).
- This NF- ⁇ B blockade in SMC correlates with suppression of NF- ⁇ B-dependent pro-inflammatory gene expression (e.g., ICAM-1) and SMC proliferation, both of which are involved in the development of atherosclerosis.
- A20 As noted above, we also discovered that expression of A20, to date viewed as an anti-apoptotic gene, sensitizes SMC to cytokine-mediated apoptosis, a surprising finding. This novel function of A20 in SMC further augments its anti-atherogenic potential by combining anti-proliferative and pro-apoptotic functions.
- SMC seem very resistant to apoptotic stimuli in vitro, including nitric oxide, oxidized LDL, high levels of cytokines (IFN- ⁇ , TNF- ⁇ an IL-1 ⁇ ), anti-oxidants such as PDTC, Fas-mediated apoptosis, and growth factor deprivation (Geng, et al., Arterioscler. Thromb. Vasc. Biol. (1996) 16:19-27; Tsai et al., J. Biol. Chem. (1996) 271:3667-3670; Björkerud et al., Arterioscler. Thromb. Vasc. Biol.
- the present invention establishes that modification of SMC to express A20 may protect vessels and vascularized organs from atherosclerosis and TAV.
- the present invention sets the basis for the use of A20 and other pro-apoptotic factors as gene therapy tools in pre-clinical and clinical protocols. This approach has immediate clinical potential in vascular conditions.
- the present invention provides a method of treating vascular disease by (1) modifying a smooth muscle cell by inserting into the smooth muscle cell a therapeutic gene that achieves an anti-inflammatory, pro-apoptotic, effect in smooth muscle cells, and (2) transplanting the smooth muscle cell, or tissue, or organ comprising the smooth muscle cell into a patient diagnosed with a vascular disease or a transplant candidate (i.e., a patient having end-stage organ failure).
- the method of the invention can be used to prevent vascular disease, for example TAV, by (1) modifying a smooth muscle cell by inserting into the smooth muscle cell a therapeutic gene that achieves an anti-inflammatory, pro-apoptotic effect in smooth muscles cells, and (2) transplanting the smooth muscle cell, or tissue, or organ comprising the smooth muscle cell into a patient at risk for developing TAV.
- Patients at risk for developing TAV include patients receiving allo- or xenogeneic tissue or organ transplants. For example, a patient scheduled to receive a heart transplant would be classified as a patient at risk for developing TAV.
- a therapeutic gene is a DNA sequence encoding a protein capable of decreasing inflammation (e.g., by inhibiting NF- ⁇ B activation in a smooth muscle cell) and increasing apoptosis in a smooth muscle cell, thus acting as a dual/anti-inflammatory, pro-apoptotic factor.
- the therapeutic gene also achieves an anti-proliferative effect in smooth muscle cells.
- the therapeutic gene further achieves an anti-inflammatory effect in endothelial cells in addition to smooth muscle cells.
- the therapeutic gene A20 has been demonstrated to have anti-inflammatory, anti-proliferative, and pro-apoptotic activities in smooth muscle cells and also retains an anti-inflammatory effect in EC.
- A20 is the therapeutic gene used in the present invention.
- the present invention utilizes a therapeutic gene encoding a mutant or derivative of the A20 protein.
- the invention comprises a method of treating a dysfunctional activation response of a smooth muscle cell to an inflammatory or other activation stimulus, by inserting into the smooth muscle cell, DNA encoding a polypeptide having the pro-apoptotic activity of an A20 protein in operative association with a suitable promoter and expressing the polypeptide at effective levels, whereby apoptosis in the smooth muscle cell is substantially activated.
- the DNA sequence including the pro-apoptotic protein or polypeptide may also include, for example, a transcriptional termination region and an appropriate signal sequence, e.g., a mitochondrial specific signal sequence to provide site-specific targeting ability to the pro-apoptotic factor.
- the promoter and/or the protein encoding region of the present invention may be heterologous (i.e., non-native) to the cell.
- one or both of the protein encoding region and the promoter region may be native to the cell.
- the promoter may be a promoter other than the promoter which normally controls expression of the pro-apoptotic factor (e.g., A20) in the cell.
- the promoter controlling the expression of the protein encoding region is a constitutive, regulable, and/or tissue specific promoter.
- a regulable promoter is that it may be inducible, that is, transcription (and thus protein expression) can be activated on demand in response to a stimulus.
- an advantage of employing an inducible promoter for transplantation purposes is that the desired high level expression of the pro-apoptotic protein or polypeptide (e.g., A20) can be obtained on demand in response to a predetermined stimulus, such as e.g., the presence of tetracycline in the cellular environment.
- a predetermined stimulus such as e.g., the presence of tetracycline in the cellular environment.
- a tetracycline-inducible promoter which is suitable for use in the invention is disclosed by Furth et al., ( PNAS USA (1994) 91:9302-9306).
- a regulable promoter system in which transcription is initiated by the withdrawal of tetracycline is described by Gossen and Bujard, ( PNAS USA (1992) 90:5547-51).
- expression of the anti-inflammatory/pro-apoptotic protein or polypeptide is induced in response to a predetermined external stimulus, and the stimulus is applied immediately prior to subjecting the SMC to an activating stimulus, so that expression, for example, of A20, is already at effective levels to block NF- ⁇ B activation and thereby inhibit inflammation and promote apoptosis.
- the anti-inflammatory/pro-apoptotic protein or polypeptide is also expressed at a level sufficient to block smooth muscle cell proliferation. The activities of blocking inflammation and proliferation are clearly anti-atherogenic.
- the invention also includes the smooth muscle cells, modified as described above, and tissues or organs comprising smooth muscle cells. Accordingly, the invention provides a smooth muscle cell modified to express A20, or a mutant or derivative of A20.
- the A20 protein is capable of inhibiting inflammation and promoting apoptosis in the presence of a cellular activating stimulus. As a result, the modified smooth muscle cell exhibits increased apoptosis relative to an untreated smooth muscle cell.
- the A20 protein is also capable of blocking smooth muscle cell proliferation.
- the present invention further provides a donor smooth muscle cell, or a tissue, or organ having the donor smooth muscle cell, for transplantation into a recipient species, wherein the donor cell is modified to express A20.
- the present invention provides an organ or vessel from a non-human transgenic or somatic recombinant mammal containing DNA encoding a pro-apoptotic protein of a different species.
- the non-human organ or vessel is a porcine organ or vessel that has been modified to express a pro-apoptotic factor.
- the pro-apoptotic factor is preferably human, for example human A20.
- Such cells, tissues and organs as described above can be used in surgical procedures such as heart, liver, or kidney transplantation. Additionally, a modified vessel according to the present invention, can be used, for example, as a vascularized organ transplant and in vascular surgery.
- the present invention provides a method of preparing a vascularized organ or vessel for transplantation into a patient including (1) obtaining an organ or vessel for transplant; and (2) perfusing the organ with nucleic acid encoding A20 protein, or mutants or derivatives thereof.
- the prepared organ or vessel is a vascularized organ or a vascular graft.
- the prepared vascularized organ or vessel can then be used, for example, in a transplantation procedure to treat a patient that has suffered ischemia, reperfusion injury, mechanical injury, immunologic injury, pharmacologic injury, coronary trauma or other vascular disease.
- the modified vascularized organ or vessel can be used in a patient who has undergone balloon angioplasty. Most preferably, the modified vascularized organ or vessel is used to replace a diseased vascularized organ or vessel.
- cells of a donor mammal may be modified according to the invention by insertion of a pro-apoptotic gene (e.g., porcine or human) under the control of a promoter which is inducible by a drug such as, for example, tetracycline.
- a pro-apoptotic gene e.g., porcine or human
- the animal whether a somatic recombinant or a transgenic, may be raised to the desired level of maturity under tetracycline-free conditions, until such time as the cells, or tissue, or organs comprising the cells, are to be surgically removed for transplantation purposes.
- the donor animal may be administered tetracycline in order to begin inducing high levels of expression of the anti-apoptotic protein.
- the organ can then be transplanted into a recipient (e.g., human), and tetracycline may continue to be administered to the recipient for a sufficient time to maintain the protein at the desired levels in the transplanted cells to inhibit NF- ⁇ B activation.
- the organ after being surgically removed from the donor, the organ can be maintained ex vivo in a tetracycline-containing medium until such time as grafting into a recipient is appropriate.
- the inserted DNA sequences are incorporated into the genome of the cell.
- the inserted DNA sequences may be maintained in the cell extrachromosomally, either stably or for a limited period.
- the modification of smooth muscle cells or endothelial cells may be carried out in vivo or ex vivo.
- the invention provides a method for substantially promoting apoptosis and substantially inhibiting inflammation in smooth muscle cells by applying an activation stimulus in vivo, to a patient in need of such therapy.
- the method includes modifying smooth muscle cells of a patient in vivo by inserting into the smooth muscle cells, DNA encoding a pro-apoptotic protein in operative association with a constitutive or inducible promoter and expressing the protein at effective levels, whereby NF- ⁇ B activation is also substantially inhibited.
- Nucleic acid molecules are provided in solution or in any other pharmacologically suitable form for administration.
- the subject compositions are administered intravascularly, particularly intraarterially.
- the target neointimal lesion may be subject to isolation, so as to limit the flow of blood or allow for an extended period of incubation.
- the blood vessels of an organ e.g., a kidney
- the active agents may be maintained in the region by virtue of having a specific affinity for target cells (perhaps via a targeting molecule), or may be allowed to flow through the vasculature.
- the time of incubation sufficient to deliver the nucleic acids to the cells of the vasculature is usually less than about one hour, more usually less than about 30 minutes, but may be for any period of time that is both effective and practical for the in vivo isolated segment of blood vessel.
- Useful delivery systems include the Sendai virus-liposome delivery systems (see Rapaport and Shai (1994) J. Biol. Chem. 269:15124-15131), cationic liposomes, polymeric delivery gels or matrices, porous balloon catheters (Shi et al. (1994) Circulation 90:955-951; and Shi et al. (1994) Gene Therapy 1:408-414), intraluminal pressure (PCT/US96/06271, herein incorporated by reference), retrovirus expression vectors, and the like.
- liposomes as delivery vehicles is one particular method of interest.
- the liposomes fuse with the cells of the target site and deliver their contents intracellularly.
- liposomes are maintained in contact with the cells for a time sufficient for fusion, using various means to maintain contact, such as isolation, binding agents, and the like.
- Liposomes may be prepared with purified proteins or peptides that mediate fusion of membranes, such as those of the Sendai virus or influenza virus, etc.
- the lipids may be any useful combination of known liposome forming lipids, including, for example, cationic lipids, such as phosphatidylcholine.
- the remaining lipid will normally be neutral lipids, such as cholesterol, phosphatidyl serine, phosphatidyl glycerol, and the like.
- Liposomes may be prepared by the procedure described by Kato et al. ( J. Biol. Chem. (1991) 266:3361). This method allows for the incorporation into the lumen, high molecular weight molecules, particularly nucleic acids of one kilobase pair or more. In this way oligonucleotides, plasmids, large genes, chromosomal fragments, viruses or viral segments may be introduced into cells efficiently.
- cell populations can be removed from the patient or donor animal, modified ex vivo by insertion of vector DNA, and re-implanted into the patient or transplanted into another recipient.
- an organ can be removed from a patient or donor and subjected to the perfusion step described above ex vivo. Following perfusion with the gene construct, the organ can be re-grafted into the patient or implanted into a different recipient of the same or different species.
- Gene transfer could also be performed in allografts or xenografts using ex vivo transduction of the organ prior to transplantation.
- transgenesis could be planned and is a well known technique in the field (see below). If successful, such an approach could be applied to all vascularized organs, especially the heart where allograft vasculopathy has emerged as the leading cause of death among transplant recipients after the first year.
- Retroviral vectors (particularly lentivirus vectors, which can infect non-replicating cells), and replication-defective retroviral vectors lacking one or more of the gag, pol, and env sequences required for retroviral replication, are well-known to the art and may be used to transform endothelial or other mammalian cells.
- PA 317 cells or other producer cell lines producing helper-free viral vectors are well-described in the literature.
- a representative retroviral construct comprises at least one viral long terminal repeat and promoter sequence upstream of the nucleotide sequence of the therapeutic substance and at least one viral long terminal repeat and polyadenylation signal downstream of the sequence.
- Vectors derived from adenoviruses i.e. viruses that cause upper respiratory disease in humans and are present in latent infections in primates, are also generally known in the art and are particularly preferred for use in the present invention.
- the ability of adenoviruses to attach to cells at low ambient temperatures is an advantage in the transplant setting which can facilitate gene transfer during cold preservation of tissues or organs.
- Adenoviral mediated gene transfer into vessels or organs by means of transduction perfusion is also a means of modifying cells in vivo. (Guzman et al. Circulation (1993) 88:2838-2848; Lemarchand, Circulation Res. (1993) 72:1132-1138)
- the method of the present invention further provides a method of preventing or treating vascular disease, for example, atherosclerosis and TAV, by transplanting donor smooth muscle cells, or graftable tissues or organs that are composed of smooth muscle cells, to a mammalian recipient having vascular disease or end-stage organ disease (i.e., any transplant candidate) by (1) modifying the donor smooth muscle cells, or progenitors cells thereof, by inserting into the smooth muscle cell, DNA encoding the A20 protein or mutant or derivative thereof; and (2) transplanting the resultant modified donor cells, or tissues or organs having such modified cells, into the recipient so that A20 is expressed in the transplanted cells, thereby substantially promoting apoptosis.
- vascular disease for example, atherosclerosis and TAV
- the donor species may be any species which is the same or different from the recipient species, and which is able to provide the appropriate cells, tissues, or organs for transplantation into the recipient species.
- the donor may be of a species which is allogeneic or xenogeneic to that of the recipient.
- the recipient is a mammal, e.g., a primate. Most preferably the recipient is human.
- human (i.e. allogeneic) as well as pig (i.e. xenogeneic) donors will be suitable, but any other mammalian species (e.g., bovine or non-human primate) may also be suitable as donors.
- porcine aortic smooth muscle cells, or the progenitor cells thereof can be modified to express porcine or human A20 protein at effective levels for grafting into a human recipient.
- Heterologous DNA encoding the A20 or another pro-apoptotic protein can be inserted into the animal or an ancestor of the animal at the single-cell stage or early morula stage.
- the preferred stage is the single-cell stage although the process may be carried out between the two and eight cell stages. A transgenic animal can thereby be obtained, which will pass the heterologous DNA on to its offspring.
- transgenic pigs are included in Example 4. Methods of preparing transgenic pigs are well known in the art, as discussed by Pinckert et al., Xeno, Vol. 2, No. 1, 1994 and the references cited therein, incorporated by reference herein. Of course, any transgenic animal may be used in the present invention. Pigs are particularly preferred because they are particularly amenable for xenotransplantation into a human recipient. Preferably, the xenotransplanted tissue is in the form of an organ, for example, kidney, heart, or liver. Transgenic pigs may be produced by homologous recombination and other such techniques that destroy wild-type gene function. By way of example, transgenic pigs may be produced utilizing homologous recombination techniques to produce a transgenic animal expressing the A20 protein, preferably the human A20 protein.
- nucleic acid encoding the preferred genes can be inserted into somatic/body cells of the donor animal to provide a somatic recombinant animal from which the DNA construct is not capable of being passed on to offspring (see, e.g., Miller, A. D. and Rosman, G. T., Biotechniques (1989) 7(9):980-990).
- Appropriate well-known methods of inserting foreign cells or DNA into animal tissue include, for example, micro-injection, embryonic stem cell manipulation, electroporation, cell gun, transduction, transfection, retroviral infection, adenoviruses, etc.
- the treated smooth muscle cells, tissue or organ may be screened for modified cells containing and expressing the construct.
- the vector construct can also be provided with a second nucleotide sequence encoding an expression product that confers resistance to a selectable marker substance. Suitable selection markers for screening include the neo gene, conferring resistance to neomycin or the neomycin analog, G418.
- a sequence encoding a tag such as green fluorescent protein (GFP) or hemaglutinin A (HA), may be attached coding region of the A20 protein.
- GFP green fluorescent protein
- HA hemaglutinin A
- any mammalian cell can be targeted for insertion of the anti-apoptotic gene, such as endothelial cells, monocytes, NK cells, lymphocytes, or islet cells
- the preferred cells for manipulation are smooth muscle cells.
- the recipient species will primarily be human, but not exclusively. Other mammals, such as non-human primates, may be suitable recipients.
- the pro-apoptotic polypeptide, or mutant or derivative thereof may be applied directly to smooth muscle cells, tissues or organs in vivo in a pharmaceutically acceptable carrier.
- modified donor smooth muscle cells and modified donor tissues and organs described above will be useful in the prevention of xenotransplant rejection (or delayed xenograft rejection or acute vascular xenograft rejection) (see, Bach et al. Immunology Today (1996) 17:379-383; Dalmasso et al., Transplantation (1991) 52:530-533).
- Xenotransplant rejection accompanies the transplantation of organs between discordant species and involves an immediate immunologic response of recipient antibodies and the complement system against the transplanted organ.
- inhibition of xenotransplant rejection may be achieved using the A20 protein of the present invention.
- This may be accomplished by providing transgenic animals that express the A20 protein of the recipient species.
- the smooth muscle cells of a donor organ obtained from such an animal can be modified by any one of the gene therapy techniques defined above.
- a vector containing DNA encoding a protein having pro-apoptotic activity can be introduced into the transgenic animal at the single cell stage or early morula stage. In this way, the resulting transgenic animal will express the complement inhibitory factors and will have smooth muscle cells as defined above.
- the invention also provides smooth muscle cells, tissue, donor organs, and non-human transgenic or somatic recombinant animals, as defined above, which express one or more human complement inhibitory factors.
- vascular grafts may also be modified and used in coronary artery bypass graft surgery or for peripheral re-vascularization of lower extremities (Mann et al., supra).
- Compound screening assays maybe used to identify bioactive agents that are capable of inducing A20-mediated apoptosis of smooth muscle cells in vascular lesion cells.
- screening assays for agents that induce A20-mediated apoptosis in smooth muscle cells yet have a low toxicity for other human cells.
- a wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, and the like.
- Three-dimensional crystal structures prepared from purified protein can be useful for modeling intermolecular interactions, etc.
- the present invention further provides a method of identifying compounds that substantially promote apoptosis and substantially inhibit smooth muscle cell growth or proliferation.
- the method includes the steps of (1) exposing smooth muscle cells to a test compound; and (2) assaying the smooth muscle cells for increased apoptosis and reduced growth or proliferation.
- a plurality of assay mixtures are run in parallel with different test compound concentrations to obtain a differential response to the various concentrations.
- one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.
- Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical, and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
- the assay of the present invention may be a binding assay, wherein one or more of the molecules may be joined to a label that can directly or indirectly provide a detectable signal.
- Various labels include radioisotopes, fluorescers, chemiluminescers, enzymes, specific binding molecules, particles, e.g. magnetic particles, and the like.
- Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc.
- the complementary member would normally be labeled with a molecule that is detectable in accordance with known procedures.
- a variety of other reagents may be included in the binding assay. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. that are used to facilitate optimal protein-protein binding and/or reduce nonspecific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc. may also be used.
- the mixture of components is added in any order that provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4° and 40° C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening. Typically between 0.1 and 1 hours will be sufficient.
- yeast double-hybrid system can be used to define new protein-protein interactions (Young, Biol. Reprod, (1998) 58(2):302-311).
- the present invention further provides a method of treating a patient having a vascularized organ transplant, a vessel transplant, or vascular disease by enhancing A20 biological activity.
- an agent Once an agent has been identified, as described above, it may be used as a therapeutic agent for vascular disease.
- the present discovery can be used to identify other potential therapeutic agents, including novel anti-atherogenic drugs.
- the present invention provides a method of preventing vascular disease in a patient by enhancing the biological activity of A20. Enhancing A20 biological activity may be accomplished, for example, by administering to the patient a therapeutic agent.
- the therapeutic agent may be any permeable factor such as a peptide or a protein, for example a cytokine, or a drug, for example, a compound identified in the screening method described above.
- the activity of A20 may be enhanced by employing a mutant of the wild-type A20 gene that encodes an A20 protein that displays increased biological activity.
- Measurement of an increase in the biological activity of A20 includes assessing as to whether there is a decrease in inflammation, an increase in apoptosis, or a decrease in proliferation in smooth muscle cells expressing A20 protein (see, Examples).
- the present invention provides a method of promoting apoptosis in smooth muscle cells in a patient by increasing the level of A20 in a patient's smooth muscle cells.
- the level of A20 may be increased is by generating smooth muscle cells that express the A20 protein at a higher level than wild-type smooth muscle cells, as described above.
- Another mechanism includes expressing a derivative or mutant of the A20 gene that encodes an A20 protein that is expressed at a higher level or has increased stability within the smooth muscle cell.
- Yet another mechanism by which this embodiment is fulfilled is by administering, to a patient, a therapeutic agent, as described above.
- the therapeutic agent may be a transcription factor, for example a transcription factor activated by an inflammatory reaction (e.g., a cytokine) that increases or stabilizes A20 expression in smooth muscle cells.
- a transcription factor activated by an inflammatory reaction e.g., a cytokine
- the therapeutic agent may be a compound that induces increased expression or stability of the A20 protein.
- A20 protein in order to assay for an increased level of A20 in a smooth muscle cell, using either a wild-type A20 protein or a mutant or derivative of A20, one would merely need to compare the quantity of A20 expression in modified and wild-type smooth muscle cells (e.g., by semi-quantitative Western blotting or quantitative PCR).
- mutants and derivatives of the A20 protein can easily be identified by introducing mutations into the A20 protein and assaying the activity of the A20 protein in smooth muscle cells as described herein. Such an analysis is currently being undertaken.
- the compounds having the desired pharmacological activity may be administered, in a physiologically acceptable carrier, to a host for treatment of vascular disease.
- a physiologically acceptable carrier for example, in Remington's Pharmaceutical Sciences, (18 th edition), ed. A. Gennaro, 1990, Mack Publishing Company, Easton, Pa., incorporated herein by reference.
- the concentration of the therapeutically active compound in the formulation may vary from about 0.1 -100 weight %.
- the therapeutic agents of the present invention may be coadministered with other agents.
- the therapeutic agents of the present invention may be coadministered with an immunoregulatory factor (e.g., an immunostimulant, i.e., a cytokine, or an immunosuppressant).
- an immunoregulatory factor e.g., an immunostimulant, i.e., a cytokine, or an immunosuppressant.
- a combination of drugs may be administered to a patient to induce a pro-apoptotic effect in smooth muscle cells.
- any of the therapeutic agents described herein may be administered along with the A20 protein, or alternatively in conjunction with the overexpression of the A20 protein in a particular organ or tissue.
- the therapeutic agents are administered at a dose effective to reduce the dimensions of a pre-existing intimal lesion.
- the lesion will be reduced in size by at least about 20% over a period of one or more weeks, more usually by at least about 50%, and may be completely regressed.
- the present invention provides a method of treating or preventing vascular disease in a patient by preparing a smooth muscle cell, or tissue or organ comprising a smooth muscle cell, for transplant by treating the smooth muscle cell, or tissue or organ comprising a smooth muscle cell, with a therapeutic agent that increases A20 biological levels, and transplanting the smooth muscle cell, or tissue or organ comprising the smooth muscle cell, treated with said therapeutic agent to a patient at risk for developing vascular disease.
- a therapeutic agent that increases the A20 level in the smooth muscle cells may be used to prepare the smooth muscle cell, or tissue, or organ for transplant.
- the smooth muscle cells, tissues or organs may be prepared in vivo, or ex vivo, as described herein above.
- A20 is Part of the Physiological response of SMC to TNF
- RNA samples were analyzed by Northern blot analysis for the expression of A20 using an A20 cDNA probe (Ferran et al., supra). In all experiments, a cDNA probe for human GAPDH was used to evaluate equal loading of RNA. Results showed almost no A20 mRNA expression prior to TNF addition.
- A20 mRNA was strongly induced 1 h following TNF stimulation and started declining 6 h thereafter (FIG. 1A).
- the induction of A20 by TNF was confirmed at the protein level by means of immunohistochemistry using a rabbit anti-human A20 polyclonal antibody developed in the laboratory (Ferran et al., supra).
- A20 protein expression was detected in the cytoplasm of SMC 4 h following TNF treatment (FIG. 1B).
- Vascular SMC at sites of atherosclerotic lesions and TAV, express features of inflammatory processes, including increased expression of genes encoding growth factors and inducible surface proteins such as adhesion molecules, iNOS, CD40 and CD40L (Bourcier et al., supra; Mach et al., supra; Obrien et al., Circulation (1996) 93:672-682).
- NF- ⁇ B has emerged as a regulator of most of these molecules by vascular cells.
- Inflammatory cytokines, oxidized lipids, activated monocytes, and T cells all present in both human atheroma and TAV, activate NF- ⁇ B and elicit a pro-inflammatory phenotype in SMC.
- NF- ⁇ B is crucial for the acquisition by the SMC of the proliferative phenotype that leads to the formation of a neointima and thus development of arteriosclerotic lesions.
- A20 is a broad inhibitor of NF- ⁇ B activation in EC (Ferran et al., supra; Cooper et al., J. Biol. Chem. (1996) 271:18068-18073). We thus tested whether A20 retains this same function in SMC.
- A20 was expressed in human SMC cultures using a recombinant A20 adenovirus (rAd.A20) (kind gift of Dr. V. Dixit).
- Recombinant Ad.A20 was produced, purified, and titered as described earlier (Ferran et al., supra).
- MOI multiplicities of infection
- pfu plaque forming unit
- Expression of A20 was tested by means of immunohistochemical analysis. Results show that high expression of A20 is achieved in 95% to 100% of the SMC infected with 500 pfu of rAd.A20/cell without causing any cytotoxicity.
- Nuclear and cytoplasmic extracts were prepared, before stimulation with TNF, at 15 minutes following stimulation with TNF, and at 2 h following stimulation with 100 U/ml of TNF, from non-infected (non-infected), rAd.A20 or rAd. ⁇ -gal-infected SMC.
- NF- ⁇ B activation and binding to specific ⁇ B elements were evaluated by means of electrophoretic mobility shift assay (EMSA).
- EMSA electrophoretic mobility shift assay
- A20 expression in SMC inhibited NF- ⁇ B binding to DNA (FIG. 2A).
- ICAM1 was used as a marker of NF- ⁇ B trans-activating potential in SMC.
- the rationale for using ICAM-1 relies on its role in promoting accumulation of monocytes and lymphocytes that contribute to the development of atherosclerotic lesions.
- Up-regulation of ICAM-1 following SMC stimulation was evaluated by Northern blot analysis using specific cDNA probes available in the laboratory.
- Overexpression of A20 inhibited the up-regulation of ICAM-1 mRNA induction in SMC following TNF treatment as compared to non-infected and rAd. ⁇ -gal-infected cells (FIG. 3). These results were confirmed at the protein levels.
- MCP-1 monocyte chemottractant protein
- Up-regulation of MCP-1 following TNF treatment of SMC was therefore evaluated by Northern blot analysis using a human cDNA probe as described (Millan et al., Transplantation (1997) 63:421-429).
- Over-expression of A20 in SMC inhibited TNF-mediated up-regulation of MCP-1 mRNA as compared to not infected (NI) and rAd. ⁇ -gal-infected cells (FIG. 7).
- SMC are highly resistant to apoptosis. The molecular basis of this resistance is poorly defined. SMC are readily induced to undergo apoptosis in culture when stimulated with high doses of cytokines including interferon- ⁇ , TNF, and IL-1 ⁇ , deprived of growth factors, or exposed to oxidized LDL, NO donors or the anti-oxidant pyrrolidine dithiocarbamate (PDTC).
- cytokines including interferon- ⁇ , TNF, and IL-1 ⁇
- PDTC anti-oxidant pyrrolidine dithiocarbamate
- Non-infected, rAd.A20, rAd. ⁇ -gal or rAd.I ⁇ B ⁇ infected SMC were treated with 400 U/ml of rhuTNF, 400 U/ml rhu IFN ⁇ and 100 U/ml of rhu IL-1 ⁇ /ml. Forty-eight hours following treatment, cells were harvested, and apoptosis evaluated by DNA content analysis (Ferran et al., supra). Cells with a normal DNA content (>2N) were scored as viable, whereas cells with a hypodiploid DNA content ( ⁇ 2N, termed A0) were scored as apoptotic.
- the percentage of apoptotic SMC expressing I ⁇ B ⁇ increased from 0.8% to 16% 48 h following cytokine treatment. This data suggests that A20-induced sensitization to cytokine-mediated apoptosis is not solely related to its NF- ⁇ B inhibitory activity (FIG. 5).
- Fas Another apoptotic receptor that is expressed on vascular SMC is Fas (CD95) (Chan et al., Circ. Res. (2000) 86:1038-1046). However and despite Fas expression, many cells including SMC resist Fas-induced apoptosis. Interestingly, medial SMC show a marked heterogeneity to Fas-mediated apoptosis with their sensitivity determined not only by surface expression of Fas but also by differential expression of Fas-signaling proteins below receptor level such as caspase 3 (Chan et al., supra).
- Fas-mediated apoptosis of smooth muscle cells has been suggested as a potential means to inhibit neointima formation (Sata et al., Proc. Natl. Acad. Sci. USA (1998) 95:11213-1217). Fas ligand gene transfer to the vessels inhibits neointima formation. We thus questioned whether A20-mediated sensitization to cytokine-mediated apoptosis would also apply for Fas-mediated apoptosis.
- Non-infected, rAd.A20 or rAd. ⁇ -gal infected SMC were treated with 1 ⁇ g/ml anti-Fas antibody IgM clone CH-11 ( ⁇ Fas) (05-201 Upstate or an IgM control antibody in the presence or absence of Actinomyein D (150 nM).
- ⁇ Fas anti-Fas antibody
- 05-201 Upstate or an IgM control antibody in the presence or absence of Actinomyein D (150 nM).
- Fas-associated death doman protein FADD
- Fas-associated death doman protein FADD
- chemokines such as MCP-1 and IL-8 and cause massive immigration of macrophages in vivo at the site of atherosclerotic lesions.
- chemokines are also up-regulated during Fas-induced apoptosis in SMC.
- MCP-1 expression following ⁇ Fas treatment was analyzed by Northern blot analysis using a human MCP-1 probe. Results confirm that MCP-1 mRNA is up-regulated in SMC 4 hours following ⁇ Fas addition. Overexpression of A20 in SMC inhibited ⁇ Fas-mediated up-regulation of MCP-1 mRNA and also down-regulated the constitutive level detected in NI cells (FIG. 9).
- Protein concentration was measured using Bio-RAD D c protein assay (Bio-Rad, Hercules, Calif.) and fifteen ⁇ g of protein were resolved on reducing sodium dodecyl sulfate (SDS) polyacrylamide gels, transferred onto Immobilon-P membranes (Milipore, Bedford, Mass.) and blocked in Blotto (5% non-fat dry milk in 0.1% Tween 20 in PBS).
- Bio-RAD D c protein assay Bio-Rad, Hercules, Calif.
- SDS sodium dodecyl sulfate
- Bcl-x S/L and Bcl-2 were detected using 1/500 dilution of an anti Bcl-x S/L rabbit IgG (Santa Cruz) and a 1/1000 dilution of an anti-Bcl-2 mouse IgG1 mAb (Pharmingen, San Diego, Calif.) followed by a 1/3000 dilution of peroxydase-conjugated donkey anti-rabbit or goat anti-mouse secondary antibody (Pierce, Rockford, Ill.) and revealed by enhanced chemiluminescence (NEN, Boston, Mass.). Results indicate that expression of A20 in SMC does not modify the constitutive levels of expression of Bcl-x L nor their levels upon addition of cytokines (FIG. 10).
- a transgenic mouse line expressing A20 in EC was established using the Complement (C)1 inhibitor promoter that has been shown to induce specific expression of the transgene in EC (Dr. Mario Tozzi, personal communication). Screening for expression of A20 in EC is currently being performed to establish a line of high expressers. Analysis of A20 expression by means of immunohistochemistry shows specific expression of A20 in EC of the heart (FIG. 6A&B).
- NF-AT nuclear factor for activated T cells
- AP-1 activated protein-1
- MAPK mitogen-activated protein kinase
- SMC cultures overexpressing A20 by means of adenoviral-mediated gene transfer may be activated using oxidized LDL or CD40 cross-linking, two relevant pro-atherogenic stimuli.
- TNF has already been tested.
- Whole cells, cytoplasmic and nuclear extracts, and mRNA are harvested at different time points following these treatments and evaluated for (i) expression of the NF- ⁇ B dependent genes ICAM-1, VCAM-1, iNOS and CD40, all implicated in the pathogenesis of atherosclerosis; (ii) degradation and phosphorylation of I ⁇ B ⁇ by means of Western blot analysis; (iii) nuclear translocation of NF- ⁇ B by means of EMSA; and (iv) activation of the different kinases (IKK ⁇ , IKK ⁇ , NIK and MEKK1) involved in the signaling pathway leading to I ⁇ B ⁇ phosphorylation (Zandi et al., Mol.
- A20 may also be evaluated on NF-AT and p38 MAP kinase activation to study their potential roles in SMC proliferation and apoptosis (Jing, et al., Circ. Res. (1999) 84:831-839; Boss et al., J. Biol. Chem. (1998) 273:19664-19671). This study is performed using EMSA and kinase assays. The results obtained with A20 expressing SMC are then compared to those obtained with either non-infected, rAd. ⁇ -gal or rAd.I ⁇ B ⁇ -infected SMC control groups.
- A20 will act in an agonist independent manner as a broad inhibitor of SMC activation and that this inhibition will occur upstream of I ⁇ B ⁇ degradation and phosphorylation.
- a further delineation of a specific target of A20 in SMC provides data valuable to defining novel therapeutic strategies. These data will also determine to what extent the effect of A20 in SMC is specific to NF- ⁇ B or affects other transcription factors or signaling pathways relevant for SMC proliferation and apoptosis.
- SMC proliferation is another marker of NF- ⁇ B activation.
- SMC cultures are first serum-starved to synchronize their cell cycle within the G0 phase. SMC are then infected with rAd.A20, rAd.I ⁇ B ⁇ or rAd. ⁇ -gal. Entry into the cell cycle and proliferation are then driven by addition of serum or basic fibroblast growth factor (bFGF). Cell cycle progression is then evaluated by means of FACS analysis of DNA content and bromodeoxyuridine incorporation at 24, 48, 60 and 72 h following addition of the growth factors.
- bFGF basic fibroblast growth factor
- cell extracts and mRNA are recovered following the addition of serum to evaluate the effect of A20 expression on cyclin D1, a critical NF- ⁇ B-dependent component of the cell cycle.
- overexpression of A20 in SMC is likely to be at least as effective as I ⁇ B ⁇ in inhibiting the proliferation of SMC, with the SMC being retained within the G1 phase of the cell cycle.
- this effect relates to inhibition of the NF- ⁇ B-dependent expression of cyclin D1.
- Apoptosis is now viewed as beneficial to prevent redevelopment and promote the regression of established atherosclerotic lesions.
- the present invention demonstrates for the first time that A20 sensitizes SMC to cytokine-mediated apoptosis, making A20 a prime gene therapy target to achieve this aim.
- These experiments are planned to extend our finding that A20 sensitizes SMC to cytokine-mediated apoptosis and to other apoptotic stimuli that are present within the atherosclerotic plaque i.e. Fas, NO and oxidized LDL.
- Fas apoptotic stimuli that are present within the atherosclerotic plaque i.e. Fas, NO and oxidized LDL.
- Fas apoptotic stimuli that are present within the atherosclerotic plaque i.e. Fas, NO and oxidized LDL.
- Fas apoptotic stimuli that are present within the atherosclerotic plaque i.e
- non-infected SMC and SMC infected with rAd.A20, rAd.I ⁇ B ⁇ or rAd., ⁇ -gal are subjected to 4 different pro-apoptotic stimuli, i.e. a combination of TNF, IL-1 and IFN ⁇ , NO donors, oxidized LDL and Fas cross-linking with anti-Fas antibodies.
- pro-apoptotic stimuli i.e. a combination of TNF, IL-1 and IFN ⁇ , NO donors, oxidized LDL and Fas cross-linking with anti-Fas antibodies.
- Apoptosis is assayed at 8, 16, 24 and 48 h following stimulation by means of FACS analysis of DNA content.
- cell extracts are recovered at 3, 6, 9, 16 and 24 h to analyze (i) the effect of A20 on the activation of both initiator or class I (caspase 8) and effector or class II (caspase 3,9) caspases using specific colorimetric assays and Western blot analysis, (ii) cytochrome c release in the cytoplasm (iii) c-myc expression and (iv) cleavage of PARP.
- the effect of A20 on modification of the trans-mitochondrial membrane potential will also be evaluated.
- A20 functions to sensitize SMC to TNF-mediated apoptosis and can thus contain abnormal cell growth and proliferation. This seems especially true in an inflammatory environment (which induces expression of A20) that is encountered in rejecting allografts and in lesions of atherosclerosis.
- this effect relates to more than A20-mediated inhibition of NF- ⁇ B, because the sensitizing effect of A20 upon apoptosis is stronger than the one achieved by I ⁇ B ⁇ despite a similar blockade of NF- ⁇ B activation by A20 and I ⁇ B ⁇ . Evaluating whether A20 has additional effects on other signaling pathways involved in SMC apoptosis such as p38 MAP kinase will further determine the mechanisms by which A20 sensitizes SMC to apoptosis. This novel function of A20 in SMC may indicate specific molecular partners for A20 in SMC.
- A20 functions in vitro to inhibit SMC activation and proliferation and sensitizes SMC to cytokine-mediated apoptosis.
- A20 expression in SMC of long term surviving heart xenografts and allografts correlates with the absence of atherosclerosis.
- transgenic mouse expressing A20 in SMC under the control of one of the newly-developed SMC promoters: the Crp2/SmLim promoter or the smooth muscle heavy chain myosin gene promoter (Madsen et al., Cire. Res. (1998) 82:908-917,;Yet et al., J. Biol. Chem. (1998) 273:10530-10537).
- SMC promoters the Crp2/SmLim promoter or the smooth muscle heavy chain myosin gene promoter
- A20 is cloned under the control of these promoters and the mice are screened for the presence of the transgene by Southern blot analysis and for expression in vessels by immunohistochemistry. These mice are then used as organ donors in models of chronic allograft or xenograft rejection (Hancock et al., supra; Bach et al., Transpl. Proc. (1997) 29:56-58).
- mice may be crossed with mice expressing A20 in EC to test whether expression of A20 is required in both EC and SMC to inhibit TAV.
- Mice expressing A20 in their SMC or in their SMC and EC are then crossed with already established lines of atherosclerosis prone mice (i.e., the LDL receptor knock out or the ApoE deficient mice), to evaluate whether A20 will protect these animals from the development of atherosclerotic lesions (Breslow, Science (1996) 272:685-688).
- transgenic mouse lines Two transgenic mouse lines that may be used are the LDL-receptor deficient mice available through the Jackson Laboratory and the APO E deficient mice (Plump et al., Cell (1992) 71:343-352; Ishibashi et al., J. Clin. Invest. (1994) 93:1885-1893).
- the evaluation of the anatomical lesions and their correlation with the expression of the transgene may be performed by immunohistochemistry.
- Recombinant constructs are well known in the art, (see, Maniatis et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y.). Methods of producing transgenic mammals using recombinant constructs are well known and include, but not limited to, microinjection, embryonic stem (ES) cell manipulation, electroporation, cell gun, transfection, transduction, retroviral infection, etc. Species of constructs may be introduced individually or in groups of two or more types of constructs.
- a transgenic pig may be produced that expresses a SMC specific pro-apoptotic factor (e.g., A20).
- estrus may be synchronized in sexually mature gilts (>7 months of age) by feeding an orally active progestogen (allyl trenbolone, AT: 15 mg/gilt/day) for 12 to 14 days.
- AT allyl trenbolone
- all gilts may be given an intramuscular injection (IM) of prostaglandin F 2a (Lutalyse: 10 mg/injection) at 0800 and 1600 hours.
- IM intramuscular injection
- donor and recipient gilts may be checked twice daily for signs of estrus using a mature boar.
- Donors that exhibit estrus within 36 hours following HCG administration may be bred at 12 and 24 hours after the onset of estrus using artificial and natural (respectively) insemination.
- one- and two-cell ova may be surgically recovered from bred donors using the following procedure.
- General anesthesia may be induced by administering 0.5 mg of acepromazine/kg of body weight and 1.3 mg ketamine/kg of body weight via a peripheral ear vein.
- the reproductive tract may be exteriorized following a mid-ventral laparotomy.
- a drawn glass cannula (O.D. 5 mm, length 8 cm) may be inserted into the ostium of the oviduct and anchored to the infundibulum using a single silk (2-0) suture.
- Ova may be flushed in retrograde fashion by inserting a 20 g needle into the lumen of the oviduct 2 cm anterior to the uterotubal junction.
- Sterile Dulbecco's phosphate buffered saline (PBS) supplemented with 0.4% bovine serum albumin (BSA) may be infused into the oviduct and flushed toward the glass cannula.
- the medium may be collected into sterile 17 ⁇ 100 mm polystyrene tubes. Flushings may be transferred to 10 ⁇ 60 mm petri dishes and searched at low power (50 ⁇ ) using a Wild M3 stereomicroscope.
- All one- and two-cell ova may be washed twice in Brinster's Modified Ova Culture-3 medium (BMOC-3) supplemented with 1.5% BSA and transferred to 50 ⁇ l drops of BMOC-3 medium under oil.
- Ova may be stored at 38° C. under a 90% N 2 , 5% O 2 , 5% CO 2 atmosphere until microinjection is performed.
- One- and two-cell ova may be placed in an Eppendorf tube (15 ova per tube) containing 1 ml HEPES Medium supplemented with 1.5% BSA and centrifuged for 6 minutes at 14000 ⁇ g in order to visualize pronuclei in one-cell and nuclei in two-cell ova. Ova may then be transferred to a 5-10 ⁇ l drop of HEPES medium under oil on a depression slide.
- Microinjection may be performed using a Laborlux microscope with Nomarski optics and two Leitz micromanipulators and 10-1700 copies of construct DNA (linearized at a concentration of about 1 ng/ ⁇ l of Tris-EDTA buffer) may be injected into one pronuclei in one-cell ova or both nuclei in two-cell ova.
- Microinjected ova may be returned to microdrops of BMOC-3 medium under oil and maintained at 38° C. under a 90% N 2 , 5% CO 2 , 5% O 2 atmosphere prior to their transfer to suitable recipients. Ova may preferably be transferred within 10 hours of recovery.
- Only recipients which exhibit estrus on the same day or 24 hours later than the donors may preferably be utilized for embryo transfer. Recipients may be anesthetized as described earlier. Following exteriorization of one oviduct, at least 30 injected one-and/or two-cell ova and 4-6 control ova may be transferred in the following manner.
- the tubing from a 21 g ⁇ 3 ⁇ 4 butterfly infusion set may be connected to a 1 cc syringe.
- the ova and 1-2 mls of BMOC-3 medium may be aspirated into the tubing.
- the tubing may then be fed through the ostium of the oviduct until the tip reaches the lower third or isthmus of the oviduct.
- the ova may be subsequently expelled as the tubing is slowly withdrawn.
- the exposed portion of the reproductive tract may be bathed in a sterile 10% glycerol-0.9% saline solution and returned to the body cavity.
- the connective tissue encompassing the linea alba, the fat, and the skin may be sutured as three separate layers.
- An uninterrupted Halstead stitch may be used to close the linea alba.
- the fat and skin may be closed using a simple continuous and mattress stitch, respectively.
- a topical antibacterial agent e.g. Furazolidone
- Furazolidone may then be administered to the incision area.
- piglets Twenty-four hours after birth, all piglets may be processed, i.e. ears notched, needle teeth clipped, 1 cc of iron dextran administered, etc. A tail biopsy and blood may also be obtained from each pig.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention features a novel method of treating vascular disease that involves modifying smooth muscle cells to express a gene encoding a protein having both anti-inflammatory and pro-apoptotic activity. Preferably, the protein of the invention also has an anti-proliferative effect in smooth muscle cells. In general, the method is useful in preparing vascularized organs and vessels for transplant into a patient. Alternatively, the present invention can be applied to treat atherosclerotic lesions in damaged vessels.
Description
- The present application claims benefit to Provisional application No. 60/177,535 filed Jan. 21, 2000, the entire contents of which are incorporated herein by reference.
- The present research was supported by a grant from the National Institutes of Health (NIH) (Grant R01 Number HL57791-02).
- 1. Field of the Invention
- The present invention relates to the field of vascular disease.
- 2. Background of the Invention
- Vascular disease is the most common cause of morbidity and mortality in the western world, surpassing any other single degenerative disease. The fundamental pathology of vascular disease is an abnormal accumulation of cells within the subintimal space below the surface of the endothelial cell lining, resulting in a decrease in lumen size and tissue perfusion. This accumulation is due to the proliferation and/or migration of smooth muscle cells, and/or inflammatory cells into the intimal layer of a vessel, resulting in restricted blood flow through that vessel, i.e. neointimal occlusive lesions.
- Current efforts aimed at preventing and treating vascular disease are directed at developing improved lipid-lowering agents (e.g., for treatment of atherosclerosis) and immunosuppressive regimens. For example, lipid lowering agents are currently used in the treatment of atherosclerosis. Alternatively, immunosuppressive regimes are used in allotransplantation for prevention of transplant-associated vasculopathy (TAV), also referred to as transplant arteriosclerosis. TAV is closely related to atherosclerosis and remains the major barrier to successful transplantation (Brooks-Wilson et al.,Nature Genetics, (1999) 22:327-335; Kirk et al., Nature Medicine (1999) pages 686-693; Hancock et al., Nature Medicine, (1998) 4:1392-1396). Alternatively, surgical strategies have been developed that are aimed at bypassing the obstruction with venous conduits, or stretching the vessel to create a larger lumen by performing balloon angioplasty.
- Despite the substantial benefit attributable to the use of current cholesterol lowering and immunosuppressive drug therapies, these treatments do not achieve an acute reduction in vascular lesion size. Furthermore, bypass surgery may accelerate progressive lesion stenosis, and interventions such as balloon angioplasty often result in the development of restenosis. There exists the need of a strategy for preventing and treating vascular disease.
- The role of the protein A20 has been studied extensively in endothelial cells and suggests that A20 plays an anti-apoptotic role in response to inflammatory stimulus.
- The present invention is based on the finding that A20 is a pro-apoptotic factor in smooth muscle cells, a finding which would not have been predicted based on the anti-apoptotic role previously established for A20 in endothelial cells. The present invention thus provides therapeutic strategies for up-regulating pro-apoptotic factors in smooth muscle cells for prevention and treatment of vascular disease.
- Specifically, the present invention provides a method of treating vascular disease by (1) modifying mammalian smooth muscle cells so that they exhibit increased anti-inflammatory and pro-apoptotic activity, and (2) transplanting the smooth muscle cells into a transplant candidate or a patient diagnosed with a vascular disease (e.g., atherosclerosis, transplant-associated vasculopathy, or chronic rejection). Preferably, the smooth muscle cells are selectively treated. For example, the present invention is useful in the treatment and prevention of atherosclerosis and transplant-associated vasculopathy (TAV). The increase in anti-inflammatory and pro-apoptotic activity is accomplished by inserting into the smooth muscle cell, or a progenitor thereof, DNA encoding A20 capable of decreasing inflammation and increasing apoptosis of the smooth muscle cell. Preferably the A20 protein employed by the methods of the invention also achieves an anti-proliferative effect in the smooth muscle cell. A key feature of the invention is that the methods include introduction of nucleic acid to a tissue or organ having smooth muscle cells, such as a vessel, a heart, a kidney or a liver into smooth muscle cells.
- In a related aspect, the method of the present invention can be applied to prevent TAV in a patient at risk for developing TAV. This method involves modifying a mammalian smooth muscle cell by inserting into the smooth muscle cell DNA encoding a protein capable of decreasing inflammation and increasing apoptosis of the smooth muscle cell and transplanting the smooth muscle cell (or tissue or organ having a smooth muscle cell) into the patient. A patient classified as a patient at risk for developing TAV would be, for example, a patient receiving an organ or vessel transplant.
- Where the method of the invention is applied to the prevention or treatment of vascular disease, the anti-inflammatory/pro-apoptotic protein is preferably the A20 protein. The present invention is based on the discovery that the A20 protein, previously thought to be an anti-apoptotic factor, has pro-apoptotic activity in smooth muscle cells. Included in certain aspects of the invention is the use of mutants and derivatives of the A20 protein that may have increased activity or expression in smooth muscle cells.
- In another related aspect, the invention provides a method of treating atherosclerosis, or preventing TAV by transplanting donor smooth muscle cells, or graftable tissues or organs having smooth muscle cells into a mammalian recipient diagnosed with atherosclerosis or at risk for developing TAV. The first step requires modifying the donor smooth muscle cells, or progenitor cells thereof, by inserting therein nucleic acid encoding the A20 protein. The second step requires transplanting the resultant modified donor smooth muscle cells, or tissue, or organ comprising the cells into the recipient and expressing in the cells the A20 protein, thereby substantially promoting apoptosis. Preferably, smooth muscle cells modified by this procedure are capable of substantially inhibiting inflammation in the presence of a cellular activating stimulus (e.g., TNF).
- The present invention also provides a method of preparing a vascularized organ or vessel for transplantation into a patient by obtaining an organ or vessel for transplant and perfusing the organ with nucleic acid encoding the A20 protein. A variety of vectors are available in the art for gene transfer. Particularly preferred vectors are the adenovirus vector and the lentivirus vector. In a preferred embodiment, the organ or vessel is perfused with a gene transfer vector and an immunoregulatory factor (e.g., a cytokine). Alternatively, a therapeutic agent may be perfused into the organ or vessel to enhance the expression of A20.
- Organ and vessel transfer procedures can be most effectively applied to patients that have suffered ischemia, reperfusion injury, mechanical injury, immunologic injury, pharmacologic injury, or coronary trauma. Alternatively, methods of organ and vessel transfer can be applied to a patient who has undergone balloon angioplasty. However, the most preferred application of the organ or vessel transfer procedure of the present invention is in the treatment of patients diagnosed with atherosclerosis. Preferably, the organ or vessel being prepared is a vascularized organ transplant or a vascular graft.
- The present invention also relates to a mammalian smooth muscle cell that is modified to express the A20 protein. Expression of the A20 protein imparts on the smooth muscle cell an anti-inflammatory/pro-apoptotic effect in the presence of a cellular activating stimulus. The modified smooth muscle cell thereby exhibits increased apoptosis, relative to an untreated smooth muscle cell. In preferred embodiments, the A20 protein also blocks smooth muscle cell proliferation. Similarly, the present invention also relates to a donor smooth muscle cell, or a tissue or organ having a smooth muscle cell, for transplantation into a recipient species, wherein the cell is modified to express A20. Alternatively, a therapeutic agent may applied to the cell to enhance the expression of A20.
- In another related aspect, the invention provides an organ or vessel from a non-human transgenic or somatic recombinant mammal comprising DNA encoding a pro-apoptotic protein of a different species. The non-human transgenic or recombinant mammal thus acts as a stable source of transplant tissue. Preferably, the non-human animal is porcine and the pro-apoptotic factor is human.
- The present invention also provides a method of identifying compounds that substantially promote apoptosis and substantially inhibit growth or proliferation in smooth muscle cells. The method requires exposing smooth muscle cells to a test compound and assaying the smooth muscle cells for increased apoptosis and reduced growth or proliferation. A variety of methods are available for assaying increased apoptosis and reduced growth or proliferation. Primarily, assays that measure A20 biological activity in smooth muscle cells (i.e., the ability to promote apoptosis and inhibit proliferation) will be used to assess the effect of a compound. Alternatively, these assays represent methods of detecting binding of a compound to a pro-apoptotic protein of interest (i.e., A20). Particularly preferred compounds include compounds that enhance A20 biological activity or increase the level of A20 in a smooth muscle cell.
- In another preferred embodiment, the present invention also provides a method of treating a patient having a vascularized organ transplant, a vessel transplant, or vascular disease by enhancing A20 biological activity. Therapeutic agents, such as the compounds identified as described above, that enhance A20 biological activity, can be used to treat patients having vascularized organ transplants, vessel transplants, or vascular diseases. Such compounds can also be applied to the prevention of vascular disease in a patient. Such compounds are preferably in the form of a therapeutic agent, e.g., a cytokine, Fas, or a drug. Alternatively, a mutant A20 gene might be employed that encodes an A20 protein that exhibits increased A20 biological activity.
- The present invention also relates to a method of promoting apoptosis in smooth muscle cells in a patient, by increasing the level of A20 in the smooth muscle cells. One mechanism of achieving this goal is to modify smooth muscle cells to express A20. Another mechanism by which to achieve increased A20 expression in a smooth muscle cell is to employ a mutant of the A20 gene encoding a protein that is expressed at a higher level in A20 cells. Yet another mechanism by which the level of A20 protein can be increased in a smooth muscle cell is by administration of a therapeutic agent to the smooth muscle cell, (e.g., a cytokine, a transcription factor, Fas, or a drug). Preferably, the method is used to treat a patient with a vascularized organ transplant, a vessel transplant or vascular disease (e.g., TAV, or atherosclerosis).
- “Vascular disease,” is used herein to refer to atherosclerosis, transplant-associated vasculopathy, chronic rejection, stenosis (e.g., vein graft stenosis or peri-anastomatic prosthetic graft stenosis), restenosis (e.g., restenosis after angioplasty or stent placement, and the like), human atheroma, septic shock, and vasculitis. Vascular disease also refers to vascular conditions that develop after a surgical treatments, such as, venous bypass surgery, balloon angioplasty, post-angioplasty of atherosclerotic plaques of both coronary and peripheral arteries, and allo- and xenograft rejection. Alternatively, vascular disease is used to refer to the disease of a patient that has suffered ischemia, reperfusion injury, mechanical injury, immunologic injury, pharmacologic injury of a vessel, or coronary trauma. In yet another embodiment, the patient has undergone balloon angioplasty.
- “A20” refers to a natural mammalian A20 gene, including the cDNA or protein thereof. A20 also include derivatives having variations in the cDNA (SEQ ID NO: 1) or amino acid (SEQ ID NO:2) sequence. Included in the definition of A20 are derivatives of the A20 protein having conserved amino acid substitutions. In addition, A20 includes mutants having alterations in one or more amino acids that either maintain or increase the activity of A20. The A20 gene or protein employed in the invention may, for example, be porcine, bovine, or primate (e.g., a human), depending on the nature of the cells to be modified and the intended recipient species for transplantation.
- By “A20 gene” is meant a gene encoding a polypeptide having A20 pro-apoptotic/anti-inflammatory activity in smooth muscle cells or other biological activities described herein. An A20 gene is a gene encoding an A20 polypeptide having about 60% or greater, more preferably 70% or greater amino acid sequence identity to the A20 amino acid sequence of SEQ ID NO:2, or a portion thereof. For example, the gene may encode human or murine A20 polypeptide. An A20 gene may also be defined as encoding a polypeptide with at least 50% of the activity of the A20 polypeptides described below. Preferably, the A20 gene is a human or murine A20 gene. In a further aspect, the A20 gene of the invention is at least 70%, and more preferably at least 80%, or at least 90% homologous to SEQ ID NO:1.
- A protein or polypeptide “having A20 activity” or “A20 active protein” refers to a protein which is able to block or suppress nuclear factor κB (NF-κB) activation, and which is at least 70%, preferably at least 80%, and more preferably at least 90% (most preferably at least 95%) homologous to the protein sequence of a natural mammalian A20 protein (e.g., human) (SEQ ID NO:2) (see, Dixit et al.,J. Biol. Chem., (1990) 265:2973, and WO 05/0062, which are hereby incorporated by reference). Preferably, by blocking is meant at least 50% inhibition of IκB degradation that occurs after TNF stimulation, but blocking can also mean a 50% or greater inhibition of NFκB binding to κB elements on the DNA, or a 50% or greater decrease in the up-regulation of mRNA seen for NFκB-regulated genes following TNF treatment, such genes include, for example, ICAM-1 and MCP-1.
- By “therapeutic gene” is meant a DNA that achieves an anti-proliferative, pro-apoptotic effect in smooth muscle cells. In addition, the therapeutic gene may also have the effect of decreasing inflammation, (e.g., by inhibiting NF-κB activation in a smooth muscle cell).
- “Inflammation” refers to a cellular response to TNF that constitutes in part activation of NF-κB. An “anti-inflammatory” is a permeable factor (protein, peptide, or chemical agent (i.e., a drug)) that suppresses, inhibits or blocks the cellular response to TNF and NF-κB activation.
- “Host” or “recipient” refers to the body of the patient into whom donor biological material is grafted. Preferably, the host is an animal which is of interest for experimental investigations, providing a model for treatment of human disease. More preferably, the host is a mammal or patient, and may be any mammalian species. For example, the mammalian host may be a rodent (e.g., including mice, rats and hamsters), or another mammal (e.g., rabbits, equines, bovines, canines, felines, etc.). Such mammals are of interest for the study of experimentally induced vascular lesions. A particularly preferred host is a primate. A most preferred mammalian host is a human.
- A “patient at risk” for developing TAV may include all patients receiving allo- or xenogeneic tissue or organ transplants.
- A “vascularized organ transplant,” according to the present invention, includes any organ having vasculature and containing smooth muscle cells. For example, the heart, liver, and kidney are vascularized organs that can be used for transplant according to the present invention. “Vascularized organ transplant,” as used herein, refers to any organ that may be used in a transplant procedure to replace a like organ that has suffered end-stage organ failure.
- “Graft,” “transplant”, or “implant” are used interchangeably to refer to biological material derived from a donor for transplantation into a recipient, and to the act of placing such biological material in the recipient.
- “Allogeneic” refers to the donor and recipient being of the same species (also, allograft). As a subset thereof, “syngeneic” refers to the condition wherein donor and recipient are genetically identical. “Autologous” refers to donor and recipient being the same individual. “Xenogeneic” (and “xenograft”) refer to the condition where the graft donor and recipient are of different species.
- By “constitutive” when used in reference to a promoter is meant substantially continuous transcription of the gene and expression of the protein over the life of the cell.
- By “regulable” when used in reference to a promoter is meant that the transcription of the gene and expression of the protein is related to the presence, or absence, of a given substance. An embodiment of “regulable” expression includes “inducible” expression, i.e. whereby transcription (and thus protein expression) occurs on demand in response to a stimulus. The stimulus may comprise activating stimuli or a predetermined external stimulus. The activating stimuli may be any of the stimuli which give rise to changes in the endothelium or smooth muscle cells of donor tissue or organs which contribute to vascular disease. The predetermined external stimulus may be the presence of a drug, cytokine, or other agent. An example of a drug stimulus is tetracycline, which has the ability to activate the tetracycline responsive promoter. Alternatively, the activating stimuli may be TNF mediated NF-κB activation.
- “Candidate compound,” “test compound,” “agent,” or “therapeutic agent” as used herein include any molecule or permeable factor, e.g., a protein or pharmaceutical, i.e., a drug, with the capability of substantially promoting apoptosis and substantially inhibiting smooth muscle cell growth or proliferation.
- By “A20 biological activity” as used herein, is meant, the ability of A20 to decrease inflammation and increase apoptosis in smooth muscle cells. Preferably, A20 biological activity also includes the ability to decrease proliferation of smooth muscle cells. A variety of assays are described herein (see, Examples) that measure A20 biological activity.
- By “enhanced biological activity” as used herein in reference to the A20 protein, is meant, that the pro-apoptotic/anti-proliferative activity of the A20 protein has been increased above that of the wild-type A20 protein.
- By “increased level” as used herein, is meant that the A20 protein is present in a greater quantity or has greater biological activity in a modified smooth muscle cell compared to the level of A20 protein in an unmodified wild-type smooth muscle cell.
- FIG. 1 is a photograph of a Western blot depicting A20 expression induction by TNF (panel A) and a photograph of immunohistochemical analysis of A20 expression in smooth muscle cells after TNF treatment (panel B).
- FIG. 2 is a photograph of an electrophoretic mobility shift assay (EMSA) depicting inhibition of NF-κB binding to DNA upon A20 expression (panel A) and a photograph of a Western blot depicting inhibition of IκBα degradation in the presence of A20 (panel B).
- FIG. 3 is a photograph of a Northern blot depicting inhibition of ICAM-1 up regulation by A20.
- FIG. 4 is a graph depicting inhibition of smooth muscle cell proliferation by A20.
- FIG. 5 is a graph depicting A20-induced apoptosis of smooth muscle cells in response to cytokine treatment.
- FIG. 6 is a photograph of immunohistochemical analysis of A20 expression in heart vessels of control and transgenic mice.
- FIG. 7 is a photograph of a Northern blot showing that overexpression of A20 in SMC inhibits TNF-mediated up-regulation of MCP-1 mRNA as compared to not infected (NI) and rAd.β-gal-infected cells.
- FIG. 8 depicts the percent of not infected (NI), rAd.A20 infected, or rAd.β-gal infected cells undergoing apoptosis in response to various treatments.
- FIG. 9 is a photograph of a Northern blot showing that overexpression of A20 in SMC inhibits αFas-mediated up-regulation of MCP-1 mRNA and also down-regulates the constitutive level detected in not infected (NI) cells.
- FIG. 10 is a photograph of a Western blot indicating that expression of A20 in SMC does not modify constitutive levels of Bcl-2 or Bcl-xL expression, nor their levels upon addition of cytokines.
- The present invention provides an alternative approach to inhibiting atherosclerosis through modifying cells in the vessel wall, particularly smooth muscle cells, that appear to be involved in the development of lesions associated with vascular disease, particularly atherosclerosis and TAV. This approach may offer the advantage of protecting against atherosclerosis and TAV regardless of the factors responsible for their initiation. According to the present invention, a “therapeutic gene” encoding and expressing a therapeutic protein achieves an anti-inflammatory, pro-apoptotic effect in smooth muscle cells (SMC). Preferably, the therapeutic gene also achieves an anti-proliferative effect in smooth muscle cells. Most preferably, the therapeutic gene also achieves an anti-inflammatory effect in endothelial cells (EC).
- Atherosclerosis and Transplant Associated Vasculopathy
- Atherosclerosis may be viewed as a chronic inflammatory response to high concentrations of oxidized LDL (Steinberg,Nutrition and Biotechnology in Heart Disease and Cancer, 1995 pages 39-48; Ross, N. Engl. J Med., (1986) 314:488-500). This response consists of a series of cellular and biochemical events. The present invention is based on the concept that mediators released by cells in the lesion may contribute to the development of atherosclerosis.
- Although the initiating factors of atherosclerosis and TAV are different, fundamental pathological features are similar and relate to the dysregulation of the two major cell types of the vessel wall: SMC and EC. SMC contribute to the atherosclerotic lesion by essentially three mechanisms: (i) promotion of inflammation, (ii) aberrant SMC proliferation and migration within the neointima, and (iii) dysregulated SMC apoptosis (Ross, supra, Pomerantz et al.,Nutrition and Biotechnology in Heart Disease and Cancer 1995 page 4964; Rekhter et al., Am. J. Pathol. (1995) 147:668-667; Bennett, Cardiovasc. Res. (1999) 41:361-368; Pollman et al., Nat. Med. (1998) 4:222-227; Rekhter, Cardio. Res. (1999) 141:376-384; Koyama et al., Cell (1996) 87:1069-1078). EC cells contribute to the development of the atherosclerotic lesion by acquiring an inflammatory phenotype that promotes leukocyte infiltration, macrophage infiltration, coagulation and platelet aggregation. EC cell activation further leads to thrombosis and ischemia, foam cell development, matrix deposition, as well as promotion of SMC migration and proliferation in the neointima (Cotran et al., J Am. Soc. Nephrol. (1990) 1:225-235; Gimbrone, American Journal of Cardiology (1995) 75:67B-70B).
- Transplant-associated vasculopathy (TAV) is the main feature of chronic allograft rejection. TAV is a form of accelerated atherosclerosis resulting from a chronic inflammatory process initiated by the immune response to the allograft (Tullius et al.,Transplantation (1995) 59:2126-2128; Ardehali et al., Circulation (1995) 92:450-456). Pathologically, with the exception of foam cell development, the lesions of TAV are quite similar to those of the atherosclerotic plaque. The present invention provides insight into the pathogenesis of these related diseases and the regulatory processes which maintain the structure and homeostatic functions of a healthy vessel. Through this understanding, a strategy for protecting vessels from atherosclerosis and TAV is proposed. A20
- A20 is a zinc finger protein originally identified as a tumor necrosis factor (TNF)-inducible gene in human umbilical vein endothelial cells (HUVEC) (Opipari et al.,J. Biol. Chem. (1990) 265:14705-14708). A20 is expressed in a variety of cell types in response to a number of stimuli such as interleukin (IL)-1 in HUVEC, CD40 cross-linking in B cells, phorbol 12-myristate 13-acetate (PMA) or HTLVI Tax protein in Jurkat T cells, Epstein Barr Virus latent membrane protein-1 and lipopolysaccharide (LPS) (Tewari et al., J. Immunol. (1995) 154:1699-1706; Laherty et al., J. Biol. Chem. (1992) 267:24157-24160; Sarma et al., J. Biol. Chem. (1995) 270:12343-12346). It has been established that expression of A20 in various cell types, including EC cells, confers resistance to TNF-mediated apoptosis (Tewari et al., supra; Opipari et al., J. Biol Chem. (1992)267:12424-12427; Ferran et al., Blood (1998) 91:2249-2258). Thus, A20 has been thought of as an anti-apoptotic factor.
- Morphologically, apoptosis is characterized by loss of contact with neighboring cells, concentration of cytoplasm, endonuclease activity-associated chromatin condensation, pyknosis, and segmentation of the nucleus. Disappearance of microvilli from the cell surface and vesicle formation on the cell surface (membrane blebbing) are also observed. The remaining fragments of apoptotic body cells are phagocytosed by neighboring cells (see, Duvall, E. and Wyllie, A. H.,Immunology Today (1986) 7(4):115-119).
- Traditionally, apoptotic cell death is considered to be of fundamental importance in inflammation, embryogenesis, and lymphocyte selection. Avoidance of cell activation and apoptotic cell death accompanying inflammation, particularly in connection with organ transplantation, has become a major goal for researchers in the art. In endothelial cells, graft injury and loss occurring in connection with graft preservation techniques and accompanying graft rejection exemplify the need for prevention of such a process. However, the present invention is based on the premise that promotion of apoptosis may actually be desirable for graft preservation and prevention of atherosclerosis and TAV in certain cell types, including smooth muscle cells.
- The cDNA and deduced amino acid sequences of the human A20 gene obtained from HUVEC were published by Opipari et al. (J. Biol. Chem. (1992) 267:12424-12427), as indicated herein above. At the protein level, the deduced sequence of 790 amino acids contains within its
carboxyl terminal half 7 Cys2/Cys2 zinc finger repeats; six with the configuration Cys-X4-Cys-X11-Cys-X2-Cys and one with the configuration Cys-X2-Cys-X11-Cys-X2-Cys, wherein X is any amino acid and the subscripts represent numbers of amino acids between each of the indicated cysteines. The zinc finger repeat region is important for activity of A20 in endothelial and other cell types. A novel finger loop domain composed of 11 amino acid residues has also been identified (see Opipari et al., supra). In one embodiment of this invention, the protein having A20 activity comprises amino acid residues 386-790 of SEQ ID NO:2, comprising the zinc finger region of the native protein sequence, or a region at least 80% homologous to the residues. Another suitable truncated form of the native human protein consists essentially of residues 373-790 of SEQ ID NO:2. A person skilled in the art will appreciate that mutants useful to the invention may include the zinc finger region of the protein but are not exclusive to the zinc finger region of the protein (see, Natoli et al. J. Biol. Chem. (1998) 273:31262-31272). The mutants may be identified by introducing specific desired mutations into a particular region of the A20 gene and testing the resultant mutant protein for a desired activity. - In vitro, A20 has a dual “cytoprotective” role in EC because it is both anti-apoptotic and anti-inflammatory. In vivo, A20 is expressed in EC and SMC of long term surviving hamster to rat heart xenografts and is associated with the absence of inflammation, apoptosis, and of TAV in long term surviving hamster to rat xenograft (Bach et al.,Nature Medicine (1997) 3:196-204). It has been demonstrated that the anti-inflammatory effect of A20 is mediated via blockade of the transcription factor NF-κB (see Grilli et al., International Review of Cytology, (1993) 13:1-61).
- A20 Function In SMC and EC
- NF-κB is a transcriptional activator associated with immediate early gene expression in EC activation. NF-κB is usually sequestered in the cytoplasm in association with its inhibitor IκBα (Baldwin,Ann. Rev. Immunol. (1996) 14:649-681). Upon exposure to stimuli such as lipopolysaccharide (LPS), TNF, or oxygen radicals, IκBα is phosphorylated, ubiquitinated and subsequently degraded in the proteasome allowing translocation of NF-κB to the nucleus of the EC (Traenckner et al., EMBO J. (1994) 13:5433-5441; Traenckner et al., J. Cell Sci. Suppl. (1995) 19:79-84). In the nucleus, the binding of NF-κB to certain NF-κB binding sites (kB elements) in promoter regions of the nuclear DNA initiates transcription of genes directly or indirectly under the control of these promoters. This leads to de novo expression in EC of a number of NF-κB-dependent genes including adhesion molecules, chemokines, and pro-thrombotic factors that are the hallmarks of the inflammatory phenotype (Read et al., J. Exp. Med. (1994) 179:503-512; Bach et al., Immunological Reviews, (1994) 141:5-30; Collins, Lab. Invest. (1993) 68:499-508). EC activation promotes inflammation and can lead to apoptosis of these cells.
- Prior to the present invention, evidence from EC suggested that A20 belongs to a sub-set of TNF-inducible genes which assist in ultimately conferring resistance to TNF-induced apoptosis in EC (see, Tewari et al.,J. Immunol. (1995) 1699-1706; Ferran et al., Blood (1998) 91:2249-2258; Opipari et al., J. Biol. Chem. (1990) 285: 14705-14708; Dixit et al., J. Biol. Chem. (1990) 264, 16905-16909). It was shown that TNF induces expression of A20 in EC, through NF-κB binding sites located in the A20 promoter, extending from −45 to −54 (5′-GGAAATCCCC-3′) (SEQ ID NO:3) and from −57 to −66 (5′-GGAAAGTCCC-3′) (SEQ ID NO:4) of the A20 gene (Laherty et al., J. Biol. Chem. (1993,)268, 5032-5039; Krikos et. al., J. Biol. Chem. (1992) 267:17971-17976).
- The proliferation of SMC, like EC, requires activation of the transcription factor NF-κB, as demonstrated in vitro and in atherosclerotic plaques in vivo (Brand et al.,J Clin. Invest. (1996) 97:1715-1722; Bourcier et al., J. Biol. Chem. (1997) 272:15817-15824; Bellas et al., J. Clin. Invest. (1995) 96:2521-2527). Activation of SMC provides a critical patho-physiological basis for a variety of conditions, including allo- and xenograft rejection, vasculitis, as well as atherosclerosis and TAV. Inflammatory cytokines, CD40-CD40L cognate interactions, oxidized lipids, oxidative stress, as well as growth factors present in both human atheroma and chronic transplant vasculopathy can activate NF-κB and elicit specific functions in SMC (Obata et al., Biochem. Bioph. Res. Com. (1996) 224:27-32; Mach et al., Proc. Natl. Acad. Sci USA (1997) 94:1931-1936).
- The mode of activation of SMC proliferation via NF-κB remains unclear. However, without limiting the biochemical mechanism of the invention, we propose that NF-κB may drive the cell cycle through induction of cyclin D1, in the mid-G1 phase of the cell cycle (Hinz et al.,Mol. Cell. Biol. (1999) 19:2690-2698; Sherr et al., Cell. (1993) 73:1059-1065; Roberts, Cell (1999) 98:129-132). Inhibition of the cell cycle in SMC inhibits SMC proliferation and has been demonstrated to redirect the vascular disease response away from neointimal hyperplasia and toward medial hypertrophy (Mann et al., Proc. Natl. Acad. Sci. USA (1995) 92:4502-4506; Chang et al., Science (1995) 267:518-522; Kato et al., Exp. Mol. Pathol. (1999) 66:39-52; Yang et al., Proc. Natl. Acad. Sci. USA (1996) 93:7905-7910). In addition to its anti-proliferative effect, blockade of NF-κB would also serve an anti-inflammatory function by inhibiting the up-regulation of NF-κB dependent genes that are deleterious for the development of atherosclerosis (e.g., adhesion molecules ICAM-1 and VCAM-1, pro-inflammatory receptors CD40 and CD40L, growth factors, and matrix proteinases) (Ross et a., supra; Ardehali et al., supra; Mach et al., Nature (1998) 394:200-203).
- Clinical trials aimed at blocking a single growth or inflammatory factor have failed to show efficacy. We concluded that this is not surprising given the redundancy of the system via the multiplicity of growth factors and pro-inflammatory mediators that contribute to the pathogenesis of atherosclerosis. We proposed that a more successful approach may be to target the components of intracellular signaling cascades that are shared in response to many of these growth regulatory molecules and pro-inflammatory stimuli. We reasoned that if A20 inhibits NF-κB activation in SMC, as it does in EC, A20 expression could be instrumental in inhibiting SMC proliferation and protecting vascular tissues and organs from atherosclerosis and TAV.
- Thus, A20 provides a critical pathophysiological basis of a variety of conditions, including allo- and xenograft rejection, vasculitis and atherosclerosis. U.S. Ser. No. 08/601,515, filed Feb. 14, 1996, incorporated herein by reference, discloses the use of gene therapy techniques utilizing A20 and other anti-apoptotic/anti-inflammatory genes and their expression products to prevent and treat inflammation in endothelial cells.
- We further hypothesized that if A20 inhibits NF-κB activation in SMC as it does in EC, A20 expression could block SMC proliferation and prevent or reduce atherosclerosis and TAV. Without limiting the biochemical mechanism of the invention, we proposed that the underlying mechanism of atherosclerosis and TAV is NF-κB stimulation of SMC proliferation. Surprisingly, upon testing this hypothesis, we found that A20, typically thought to act as an anti-apoptotic factor, acts as a pro-apoptotic factor in SMC.
- Therapeutic Strategies
- The present invention provides therapeutic strategies directed at up-regulating pro-apoptotic factors (or down-regulating anti-apoptotic factors) for inhibition of vascular lesion formation and prevention or treatment of vascular disease. Preferably, the protective gene should achieve an anti-proliferative and pro-apoptotic effect in SMC. According to the present invention, protection of SMCs in the vessel wall that appear to underlie the development of lesions associated with atherosclerosis, TAV, and other vascular diseases can be achieved by modifying the SMC so that it expresses a pro-apoptotic factor.
- We demonstrate herein that A20 is expressed in SMC in response to TNF (a pro-inflammatory stimulus), establishing that A20 expression as part of the physiological response of SMC to injury (see, Example 1). In addition, we show that overexpression of A20 in SMC inhibits NF-κB activation in response to TNF (see, Example 1). This NF-κB blockade in SMC correlates with suppression of NF-κB-dependent pro-inflammatory gene expression (e.g., ICAM-1) and SMC proliferation, both of which are involved in the development of atherosclerosis.
- As noted above, we also discovered that expression of A20, to date viewed as an anti-apoptotic gene, sensitizes SMC to cytokine-mediated apoptosis, a surprising finding. This novel function of A20 in SMC further augments its anti-atherogenic potential by combining anti-proliferative and pro-apoptotic functions. Interestingly, SMC seem very resistant to apoptotic stimuli in vitro, including nitric oxide, oxidized LDL, high levels of cytokines (IFN-γ, TNF-α an IL-1β), anti-oxidants such as PDTC, Fas-mediated apoptosis, and growth factor deprivation (Geng, et al.,Arterioscler. Thromb. Vasc. Biol. (1996) 16:19-27; Tsai et al., J. Biol. Chem. (1996) 271:3667-3670; Björkerud et al., Arterioscler. Thromb. Vasc. Biol. (1996) 16:415-424; Pollman et al., Circ. Res. (1996) 79:748-756; Fox et al., J. Biol. Chem. (1996) 271:12578-12584). Furthermore, we found that sensitization of SMC to apoptosis by expressing A20 is more potent than for cells expressing IκBα (the specific inhibitor of NF-κB), suggesting that A20 has targets in SMC other than NF-κB.
- The present invention establishes that modification of SMC to express A20 may protect vessels and vascularized organs from atherosclerosis and TAV. The results described herein combined with our finding that A20 is expressed in SMC of long term surviving hamster to rat heart xenografts lacking transplant arteriosclerosis (Bach et al., supra) lend support to this proposal. Thus, the present invention sets the basis for the use of A20 and other pro-apoptotic factors as gene therapy tools in pre-clinical and clinical protocols. This approach has immediate clinical potential in vascular conditions.
- The present invention provides a method of treating vascular disease by (1) modifying a smooth muscle cell by inserting into the smooth muscle cell a therapeutic gene that achieves an anti-inflammatory, pro-apoptotic, effect in smooth muscle cells, and (2) transplanting the smooth muscle cell, or tissue, or organ comprising the smooth muscle cell into a patient diagnosed with a vascular disease or a transplant candidate (i.e., a patient having end-stage organ failure).
- Alternatively, the method of the invention can be used to prevent vascular disease, for example TAV, by (1) modifying a smooth muscle cell by inserting into the smooth muscle cell a therapeutic gene that achieves an anti-inflammatory, pro-apoptotic effect in smooth muscles cells, and (2) transplanting the smooth muscle cell, or tissue, or organ comprising the smooth muscle cell into a patient at risk for developing TAV. Patients at risk for developing TAV include patients receiving allo- or xenogeneic tissue or organ transplants. For example, a patient scheduled to receive a heart transplant would be classified as a patient at risk for developing TAV.
- According to the present invention, a therapeutic gene is a DNA sequence encoding a protein capable of decreasing inflammation (e.g., by inhibiting NF-κB activation in a smooth muscle cell) and increasing apoptosis in a smooth muscle cell, thus acting as a dual/anti-inflammatory, pro-apoptotic factor. In preferred embodiments, the therapeutic gene also achieves an anti-proliferative effect in smooth muscle cells. Most preferably, the therapeutic gene further achieves an anti-inflammatory effect in endothelial cells in addition to smooth muscle cells. The therapeutic gene A20 has been demonstrated to have anti-inflammatory, anti-proliferative, and pro-apoptotic activities in smooth muscle cells and also retains an anti-inflammatory effect in EC. Thus, according to a most preferred embodiment of the invention, A20 is the therapeutic gene used in the present invention. Alternatively, the present invention utilizes a therapeutic gene encoding a mutant or derivative of the A20 protein.
- In a related aspect, the invention comprises a method of treating a dysfunctional activation response of a smooth muscle cell to an inflammatory or other activation stimulus, by inserting into the smooth muscle cell, DNA encoding a polypeptide having the pro-apoptotic activity of an A20 protein in operative association with a suitable promoter and expressing the polypeptide at effective levels, whereby apoptosis in the smooth muscle cell is substantially activated. The DNA sequence including the pro-apoptotic protein or polypeptide may also include, for example, a transcriptional termination region and an appropriate signal sequence, e.g., a mitochondrial specific signal sequence to provide site-specific targeting ability to the pro-apoptotic factor.
- The promoter and/or the protein encoding region of the present invention may be heterologous (i.e., non-native) to the cell. Alternatively, one or both of the protein encoding region and the promoter region may be native to the cell. The promoter may be a promoter other than the promoter which normally controls expression of the pro-apoptotic factor (e.g., A20) in the cell. Preferably the promoter controlling the expression of the protein encoding region is a constitutive, regulable, and/or tissue specific promoter. One feature of a regulable promoter is that it may be inducible, that is, transcription (and thus protein expression) can be activated on demand in response to a stimulus. An advantage of employing an inducible promoter for transplantation purposes is that the desired high level expression of the pro-apoptotic protein or polypeptide (e.g., A20) can be obtained on demand in response to a predetermined stimulus, such as e.g., the presence of tetracycline in the cellular environment. An example of a tetracycline-inducible promoter which is suitable for use in the invention is disclosed by Furth et al., (PNAS USA (1994) 91:9302-9306). A regulable promoter system in which transcription is initiated by the withdrawal of tetracycline is described by Gossen and Bujard, (PNAS USA (1992) 90:5547-51).
- Preferably, expression of the anti-inflammatory/pro-apoptotic protein or polypeptide is induced in response to a predetermined external stimulus, and the stimulus is applied immediately prior to subjecting the SMC to an activating stimulus, so that expression, for example, of A20, is already at effective levels to block NF-κB activation and thereby inhibit inflammation and promote apoptosis. Preferably, the anti-inflammatory/pro-apoptotic protein or polypeptide is also expressed at a level sufficient to block smooth muscle cell proliferation. The activities of blocking inflammation and proliferation are clearly anti-atherogenic.
- It is preferred that the invention also includes the smooth muscle cells, modified as described above, and tissues or organs comprising smooth muscle cells. Accordingly, the invention provides a smooth muscle cell modified to express A20, or a mutant or derivative of A20. In preferred embodiments, the A20 protein is capable of inhibiting inflammation and promoting apoptosis in the presence of a cellular activating stimulus. As a result, the modified smooth muscle cell exhibits increased apoptosis relative to an untreated smooth muscle cell. Preferably, the A20 protein is also capable of blocking smooth muscle cell proliferation. Accordingly, the present invention further provides a donor smooth muscle cell, or a tissue, or organ having the donor smooth muscle cell, for transplantation into a recipient species, wherein the donor cell is modified to express A20.
- In yet another related aspect, the present invention provides an organ or vessel from a non-human transgenic or somatic recombinant mammal containing DNA encoding a pro-apoptotic protein of a different species. Preferably, the non-human organ or vessel is a porcine organ or vessel that has been modified to express a pro-apoptotic factor. The pro-apoptotic factor is preferably human, for example human A20.
- Such cells, tissues and organs as described above can be used in surgical procedures such as heart, liver, or kidney transplantation. Additionally, a modified vessel according to the present invention, can be used, for example, as a vascularized organ transplant and in vascular surgery.
- In a related aspect, the present invention provides a method of preparing a vascularized organ or vessel for transplantation into a patient including (1) obtaining an organ or vessel for transplant; and (2) perfusing the organ with nucleic acid encoding A20 protein, or mutants or derivatives thereof. Preferably, the prepared organ or vessel is a vascularized organ or a vascular graft. The prepared vascularized organ or vessel can then be used, for example, in a transplantation procedure to treat a patient that has suffered ischemia, reperfusion injury, mechanical injury, immunologic injury, pharmacologic injury, coronary trauma or other vascular disease. Alternatively, the modified vascularized organ or vessel can be used in a patient who has undergone balloon angioplasty. Most preferably, the modified vascularized organ or vessel is used to replace a diseased vascularized organ or vessel.
- For example, cells of a donor mammal (e.g., porcine) may be modified according to the invention by insertion of a pro-apoptotic gene (e.g., porcine or human) under the control of a promoter which is inducible by a drug such as, for example, tetracycline. The animal, whether a somatic recombinant or a transgenic, may be raised to the desired level of maturity under tetracycline-free conditions, until such time as the cells, or tissue, or organs comprising the cells, are to be surgically removed for transplantation purposes. In such case, prior to surgical removal of the organ, the donor animal may be administered tetracycline in order to begin inducing high levels of expression of the anti-apoptotic protein. The organ can then be transplanted into a recipient (e.g., human), and tetracycline may continue to be administered to the recipient for a sufficient time to maintain the protein at the desired levels in the transplanted cells to inhibit NF-κB activation.
- Alternatively, after being surgically removed from the donor, the organ can be maintained ex vivo in a tetracycline-containing medium until such time as grafting into a recipient is appropriate.
- Preferably, the inserted DNA sequences are incorporated into the genome of the cell. Alternatively, the inserted DNA sequences may be maintained in the cell extrachromosomally, either stably or for a limited period.
- The modification of smooth muscle cells or endothelial cells, according to the invention, may be carried out in vivo or ex vivo. Thus, in one aspect, the invention provides a method for substantially promoting apoptosis and substantially inhibiting inflammation in smooth muscle cells by applying an activation stimulus in vivo, to a patient in need of such therapy. The method includes modifying smooth muscle cells of a patient in vivo by inserting into the smooth muscle cells, DNA encoding a pro-apoptotic protein in operative association with a constitutive or inducible promoter and expressing the protein at effective levels, whereby NF-κB activation is also substantially inhibited.
- Nucleic acid molecules are provided in solution or in any other pharmacologically suitable form for administration. Conveniently, the subject compositions are administered intravascularly, particularly intraarterially. The target neointimal lesion may be subject to isolation, so as to limit the flow of blood or allow for an extended period of incubation. For example, the blood vessels of an organ (e.g., a kidney) can be temporarily clamped off from the blood circulation of the patient, and the vessels perfused with a solution comprising a transmissible vector construct containing the subject pro-apoptotic gene, for a time sufficient for at least some cells of the organ to be modified by insertion therein of the vector construct. Upon removal of the clamps, blood flow can then be restored to the organ and its normal functioning resumed. Alternatively, the active agents may be maintained in the region by virtue of having a specific affinity for target cells (perhaps via a targeting molecule), or may be allowed to flow through the vasculature. The time of incubation sufficient to deliver the nucleic acids to the cells of the vasculature is usually less than about one hour, more usually less than about 30 minutes, but may be for any period of time that is both effective and practical for the in vivo isolated segment of blood vessel.
- There are many delivery methods known in the art for enhancing the uptake of nucleic acids by cells. Useful delivery systems include the Sendai virus-liposome delivery systems (see Rapaport and Shai (1994)J. Biol. Chem. 269:15124-15131), cationic liposomes, polymeric delivery gels or matrices, porous balloon catheters (Shi et al. (1994) Circulation 90:955-951; and Shi et al. (1994) Gene Therapy 1:408-414), intraluminal pressure (PCT/US96/06271, herein incorporated by reference), retrovirus expression vectors, and the like.
- The use of liposomes as delivery vehicles is one particular method of interest. The liposomes fuse with the cells of the target site and deliver their contents intracellularly. As noted above, liposomes are maintained in contact with the cells for a time sufficient for fusion, using various means to maintain contact, such as isolation, binding agents, and the like. Liposomes may be prepared with purified proteins or peptides that mediate fusion of membranes, such as those of the Sendai virus or influenza virus, etc. The lipids may be any useful combination of known liposome forming lipids, including, for example, cationic lipids, such as phosphatidylcholine. The remaining lipid will normally be neutral lipids, such as cholesterol, phosphatidyl serine, phosphatidyl glycerol, and the like.
- Liposomes may be prepared by the procedure described by Kato et al. (J. Biol. Chem. (1991) 266:3361). This method allows for the incorporation into the lumen, high molecular weight molecules, particularly nucleic acids of one kilobase pair or more. In this way oligonucleotides, plasmids, large genes, chromosomal fragments, viruses or viral segments may be introduced into cells efficiently.
- In another aspect, cell populations can be removed from the patient or donor animal, modified ex vivo by insertion of vector DNA, and re-implanted into the patient or transplanted into another recipient. For example, an organ can be removed from a patient or donor and subjected to the perfusion step described above ex vivo. Following perfusion with the gene construct, the organ can be re-grafted into the patient or implanted into a different recipient of the same or different species.
- Gene transfer could also be performed in allografts or xenografts using ex vivo transduction of the organ prior to transplantation. For xenotransplantation, transgenesis could be planned and is a well known technique in the field (see below). If successful, such an approach could be applied to all vascularized organs, especially the heart where allograft vasculopathy has emerged as the leading cause of death among transplant recipients after the first year.
- For gene delivery, a variety of vectors or plasmids are available (see, Maniatis et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y.; Ausubel et al.,Current Protocols in Molecular Biology, Greene Publishing Associates, New York, V. 1&2 1996; Harlow and Lane Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, incorporated by reference herein). The common vectors described herein are able to transiently or stably be maintained in smooth muscle cells, usually for a period of at least about one day, more usually for a period of at least about several days.
- Retroviral vectors (particularly lentivirus vectors, which can infect non-replicating cells), and replication-defective retroviral vectors lacking one or more of the gag, pol, and env sequences required for retroviral replication, are well-known to the art and may be used to transform endothelial or other mammalian cells. PA 317 cells or other producer cell lines producing helper-free viral vectors are well-described in the literature. A representative retroviral construct comprises at least one viral long terminal repeat and promoter sequence upstream of the nucleotide sequence of the therapeutic substance and at least one viral long terminal repeat and polyadenylation signal downstream of the sequence.
- Vectors derived from adenoviruses, i.e. viruses that cause upper respiratory disease in humans and are present in latent infections in primates, are also generally known in the art and are particularly preferred for use in the present invention. The ability of adenoviruses to attach to cells at low ambient temperatures is an advantage in the transplant setting which can facilitate gene transfer during cold preservation of tissues or organs. Adenoviral mediated gene transfer into vessels or organs by means of transduction perfusion is also a means of modifying cells in vivo. (Guzman et al.Circulation (1993) 88:2838-2848; Lemarchand, Circulation Res. (1993) 72:1132-1138)
- Accordingly, the method of the present invention further provides a method of preventing or treating vascular disease, for example, atherosclerosis and TAV, by transplanting donor smooth muscle cells, or graftable tissues or organs that are composed of smooth muscle cells, to a mammalian recipient having vascular disease or end-stage organ disease (i.e., any transplant candidate) by (1) modifying the donor smooth muscle cells, or progenitors cells thereof, by inserting into the smooth muscle cell, DNA encoding the A20 protein or mutant or derivative thereof; and (2) transplanting the resultant modified donor cells, or tissues or organs having such modified cells, into the recipient so that A20 is expressed in the transplanted cells, thereby substantially promoting apoptosis.
- The donor species may be any species which is the same or different from the recipient species, and which is able to provide the appropriate cells, tissues, or organs for transplantation into the recipient species. The donor may be of a species which is allogeneic or xenogeneic to that of the recipient. Preferably, the recipient is a mammal, e.g., a primate. Most preferably the recipient is human. For human recipients, it is envisaged that human (i.e. allogeneic) as well as pig (i.e. xenogeneic) donors will be suitable, but any other mammalian species (e.g., bovine or non-human primate) may also be suitable as donors. For example, porcine aortic smooth muscle cells, or the progenitor cells thereof, can be modified to express porcine or human A20 protein at effective levels for grafting into a human recipient.
- Heterologous DNA encoding the A20 or another pro-apoptotic protein can be inserted into the animal or an ancestor of the animal at the single-cell stage or early morula stage. The preferred stage is the single-cell stage although the process may be carried out between the two and eight cell stages. A transgenic animal can thereby be obtained, which will pass the heterologous DNA on to its offspring.
- Methods of preparing transgenic pigs are included in Example 4. Methods of preparing transgenic pigs are well known in the art, as discussed by Pinckert et al.,Xeno, Vol. 2, No. 1, 1994 and the references cited therein, incorporated by reference herein. Of course, any transgenic animal may be used in the present invention. Pigs are particularly preferred because they are particularly amenable for xenotransplantation into a human recipient. Preferably, the xenotransplanted tissue is in the form of an organ, for example, kidney, heart, or liver. Transgenic pigs may be produced by homologous recombination and other such techniques that destroy wild-type gene function. By way of example, transgenic pigs may be produced utilizing homologous recombination techniques to produce a transgenic animal expressing the A20 protein, preferably the human A20 protein.
- In another aspect, nucleic acid encoding the preferred genes can be inserted into somatic/body cells of the donor animal to provide a somatic recombinant animal from which the DNA construct is not capable of being passed on to offspring (see, e.g., Miller, A. D. and Rosman, G. T.,Biotechniques (1989) 7(9):980-990). Appropriate well-known methods of inserting foreign cells or DNA into animal tissue include, for example, micro-injection, embryonic stem cell manipulation, electroporation, cell gun, transduction, transfection, retroviral infection, adenoviruses, etc.
- Prior to implantation into a recipient species, the treated smooth muscle cells, tissue or organ may be screened for modified cells containing and expressing the construct. For this purpose, the vector construct can also be provided with a second nucleotide sequence encoding an expression product that confers resistance to a selectable marker substance. Suitable selection markers for screening include the neo gene, conferring resistance to neomycin or the neomycin analog, G418. Alternatively, a sequence encoding a tag, such as green fluorescent protein (GFP) or hemaglutinin A (HA), may be attached coding region of the A20 protein. Such tags are currently available and in use in our laboratory. Although any mammalian cell can be targeted for insertion of the anti-apoptotic gene, such as endothelial cells, monocytes, NK cells, lymphocytes, or islet cells, the preferred cells for manipulation are smooth muscle cells. The recipient species will primarily be human, but not exclusively. Other mammals, such as non-human primates, may be suitable recipients.
- In an alternative embodiment of the invention, the pro-apoptotic polypeptide, or mutant or derivative thereof, may be applied directly to smooth muscle cells, tissues or organs in vivo in a pharmaceutically acceptable carrier.
- It will be appreciated that the modified donor smooth muscle cells and modified donor tissues and organs described above will be useful in the prevention of xenotransplant rejection (or delayed xenograft rejection or acute vascular xenograft rejection) (see, Bach et al.Immunology Today (1996) 17:379-383; Dalmasso et al., Transplantation (1991) 52:530-533). Xenotransplant rejection accompanies the transplantation of organs between discordant species and involves an immediate immunologic response of recipient antibodies and the complement system against the transplanted organ.
- As described herein, inhibition of xenotransplant rejection may be achieved using the A20 protein of the present invention. This may be accomplished by providing transgenic animals that express the A20 protein of the recipient species. The smooth muscle cells of a donor organ obtained from such an animal can be modified by any one of the gene therapy techniques defined above. Alternatively, a vector containing DNA encoding a protein having pro-apoptotic activity can be introduced into the transgenic animal at the single cell stage or early morula stage. In this way, the resulting transgenic animal will express the complement inhibitory factors and will have smooth muscle cells as defined above. Thus, in a further aspect, the invention also provides smooth muscle cells, tissue, donor organs, and non-human transgenic or somatic recombinant animals, as defined above, which express one or more human complement inhibitory factors.
- It will be appreciated by those skilled in the art that the present invention can be applied to prevent or treat a variety of vascular conditions. As described herein, direct adenoviral-mediated transduction of vessels can be used to treat ischemia/reperfusion injuries and post-angioplasty of atherosclerotic plaques of both coronary and peripheral arteries. In addition, as described above, venous grafts may also be modified and used in coronary artery bypass graft surgery or for peripheral re-vascularization of lower extremities (Mann et al., supra).
- Identifying Thierapeutic Compounds
- Compound screening assays maybe used to identify bioactive agents that are capable of inducing A20-mediated apoptosis of smooth muscle cells in vascular lesion cells. Of particular interest are screening assays for agents that induce A20-mediated apoptosis in smooth muscle cells, yet have a low toxicity for other human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, and the like. Three-dimensional crystal structures prepared from purified protein can be useful for modeling intermolecular interactions, etc.
- Accordingly, the present invention further provides a method of identifying compounds that substantially promote apoptosis and substantially inhibit smooth muscle cell growth or proliferation. The method includes the steps of (1) exposing smooth muscle cells to a test compound; and (2) assaying the smooth muscle cells for increased apoptosis and reduced growth or proliferation. For example, one could assay for binding of the test compound compared to A20. Preferably, one could assay for activation of A20 activity. Generally a plurality of assay mixtures are run in parallel with different test compound concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.
- Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical, and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
- The assay of the present invention may be a binding assay, wherein one or more of the molecules may be joined to a label that can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemiluminescers, enzymes, specific binding molecules, particles, e.g. magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule that is detectable in accordance with known procedures.
- A variety of other reagents may be included in the binding assay. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. that are used to facilitate optimal protein-protein binding and/or reduce nonspecific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc. may also be used. The mixture of components is added in any order that provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4° and 40° C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening. Typically between 0.1 and 1 hours will be sufficient.
- Alternatively, the well known yeast double-hybrid system can be used to define new protein-protein interactions (Young,Biol. Reprod, (1998) 58(2):302-311).
- Drug Treatment
- The present invention further provides a method of treating a patient having a vascularized organ transplant, a vessel transplant, or vascular disease by enhancing A20 biological activity. Once an agent has been identified, as described above, it may be used as a therapeutic agent for vascular disease. Thus, the present discovery can be used to identify other potential therapeutic agents, including novel anti-atherogenic drugs. Alternatively, the present invention provides a method of preventing vascular disease in a patient by enhancing the biological activity of A20. Enhancing A20 biological activity may be accomplished, for example, by administering to the patient a therapeutic agent. The therapeutic agent may be any permeable factor such as a peptide or a protein, for example a cytokine, or a drug, for example, a compound identified in the screening method described above. Alternatively, the activity of A20 may be enhanced by employing a mutant of the wild-type A20 gene that encodes an A20 protein that displays increased biological activity. Measurement of an increase in the biological activity of A20 includes assessing as to whether there is a decrease in inflammation, an increase in apoptosis, or a decrease in proliferation in smooth muscle cells expressing A20 protein (see, Examples).
- In other preferred embodiments, the present invention provides a method of promoting apoptosis in smooth muscle cells in a patient by increasing the level of A20 in a patient's smooth muscle cells. Of course, it will be appreciated that one mechanism by which the level of A20 may be increased is by generating smooth muscle cells that express the A20 protein at a higher level than wild-type smooth muscle cells, as described above. Another mechanism includes expressing a derivative or mutant of the A20 gene that encodes an A20 protein that is expressed at a higher level or has increased stability within the smooth muscle cell. Yet another mechanism by which this embodiment is fulfilled is by administering, to a patient, a therapeutic agent, as described above. In the present embodiment, the therapeutic agent may be a transcription factor, for example a transcription factor activated by an inflammatory reaction (e.g., a cytokine) that increases or stabilizes A20 expression in smooth muscle cells. Alternatively, the therapeutic agent may be a compound that induces increased expression or stability of the A20 protein.
- One skilled in the art would appreciate that in order to assay for an increased level of A20 in a smooth muscle cell, using either a wild-type A20 protein or a mutant or derivative of A20, one would merely need to compare the quantity of A20 expression in modified and wild-type smooth muscle cells (e.g., by semi-quantitative Western blotting or quantitative PCR). Likewise, one skilled in the art would appreciate that mutants and derivatives of the A20 protein can easily be identified by introducing mutations into the A20 protein and assaying the activity of the A20 protein in smooth muscle cells as described herein. Such an analysis is currently being undertaken.
- The compounds having the desired pharmacological activity may be administered, in a physiologically acceptable carrier, to a host for treatment of vascular disease. Depending upon the manner of introduction, the compounds may be provided in a variety of physiologically acceptable carriers and formulations known to one skilled in the art and described, for example, inRemington's Pharmaceutical Sciences, (18th edition), ed. A. Gennaro, 1990, Mack Publishing Company, Easton, Pa., incorporated herein by reference. The concentration of the therapeutically active compound in the formulation may vary from about 0.1 -100 weight %.
- It will be appreciated that the therapeutic agents of the present invention may be coadministered with other agents. For example, the therapeutic agents of the present invention may be coadministered with an immunoregulatory factor (e.g., an immunostimulant, i.e., a cytokine, or an immunosuppressant). Alternatively, a combination of drugs may be administered to a patient to induce a pro-apoptotic effect in smooth muscle cells. Of course, any of the therapeutic agents described herein may be administered along with the A20 protein, or alternatively in conjunction with the overexpression of the A20 protein in a particular organ or tissue.
- The therapeutic agents are administered at a dose effective to reduce the dimensions of a pre-existing intimal lesion. Usually the lesion will be reduced in size by at least about 20% over a period of one or more weeks, more usually by at least about 50%, and may be completely regressed.
- In an alternative embodiment, the present invention provides a method of treating or preventing vascular disease in a patient by preparing a smooth muscle cell, or tissue or organ comprising a smooth muscle cell, for transplant by treating the smooth muscle cell, or tissue or organ comprising a smooth muscle cell, with a therapeutic agent that increases A20 biological levels, and transplanting the smooth muscle cell, or tissue or organ comprising the smooth muscle cell, treated with said therapeutic agent to a patient at risk for developing vascular disease. In a related embodiment, a therapeutic agent that increases the A20 level in the smooth muscle cells may be used to prepare the smooth muscle cell, or tissue, or organ for transplant. According to the present invention, the smooth muscle cells, tissues or organs may be prepared in vivo, or ex vivo, as described herein above.
- The present invention will now be illustrated by the following non-limiting examples. The following example demonstrate the anti-inflammatory/anti-proliferative/pro-apoptotic effect of A20 in smooth muscle cells.
- A20 is Part of the Physiological response of SMC to TNF
- Primary human aortic SMC were cultured in 6 well plates using smooth muscle basal medium (SmBM) (Clonetics, California) supplemented with growth factors, Gentamycin and Amphotericin B. Confluent cells were stimulated with 100 Units of recombinant human (rhu)TNF and RNA was extracted before and at 1 and 6 hours (h) following addition of TNE. RNA samples were analyzed by Northern blot analysis for the expression of A20 using an A20 cDNA probe (Ferran et al., supra). In all experiments, a cDNA probe for human GAPDH was used to evaluate equal loading of RNA. Results showed almost no A20 mRNA expression prior to TNF addition. A20 mRNA was strongly induced 1 h following TNF stimulation and started declining 6 h thereafter (FIG. 1A). The induction of A20 by TNF was confirmed at the protein level by means of immunohistochemistry using a rabbit anti-human A20 polyclonal antibody developed in the laboratory (Ferran et al., supra). A20 protein expression was detected in the cytoplasm of SMC 4 h following TNF treatment (FIG. 1B).
- A20 Inhibits NF-κB-Activation in SMC
- Vascular SMC, at sites of atherosclerotic lesions and TAV, express features of inflammatory processes, including increased expression of genes encoding growth factors and inducible surface proteins such as adhesion molecules, iNOS, CD40 and CD40L (Bourcier et al., supra; Mach et al., supra; Obrien et al.,Circulation (1996) 93:672-682). NF-κB has emerged as a regulator of most of these molecules by vascular cells. Inflammatory cytokines, oxidized lipids, activated monocytes, and T cells, all present in both human atheroma and TAV, activate NF-κB and elicit a pro-inflammatory phenotype in SMC. In addition to the pro-inflammatory phenotype, activation of NF-κB is crucial for the acquisition by the SMC of the proliferative phenotype that leads to the formation of a neointima and thus development of arteriosclerotic lesions. We had previously shown that A20 is a broad inhibitor of NF-κB activation in EC (Ferran et al., supra; Cooper et al., J. Biol. Chem. (1996) 271:18068-18073). We thus tested whether A20 retains this same function in SMC.
- A20 was expressed in human SMC cultures using a recombinant A20 adenovirus (rAd.A20) (kind gift of Dr. V. Dixit). Recombinant Ad.A20 was produced, purified, and titered as described earlier (Ferran et al., supra). In preliminary experiments, different multiplicities of infection (MOI), ranging from 100 to 1,000 plaque forming unit (pfu)/cell, were evaluated. Expression of A20 was tested by means of immunohistochemical analysis. Results show that high expression of A20 is achieved in 95% to 100% of the SMC infected with 500 pfu of rAd.A20/cell without causing any cytotoxicity.
- Nuclear and cytoplasmic extracts were prepared, before stimulation with TNF, at 15 minutes following stimulation with TNF, and at 2 h following stimulation with 100 U/ml of TNF, from non-infected (non-infected), rAd.A20 or rAd.β-gal-infected SMC. NF-κB activation and binding to specific κB elements were evaluated by means of electrophoretic mobility shift assay (EMSA). A20 expression in SMC inhibited NF-κB binding to DNA (FIG. 2A).
- We also determined where the signaling pathway leading to NF-κB activation is blocked by A20 in SMC. Cytoplasmic extracts were run on SDS-PAGE 12.5% minigels. IκBα was detected using a rabbit polyclonal IgG antibody (C21 from Santa Cruz) and a peroxidase-conjugated goat anti-rabbit secondary antibody followed by enhanced chemiluminescence detection. A20 expression in SMC inhibited the usual IκBα degradation that occurs 15 minutes following TNF stimulation (FIG. 2B). These results demonstrate that A20 interferes with signaling pathways leading to NF-κB activation at a level upstream of IκBα degradation.
- Overexpression of A20 Inhibits the Up-Regulation of a NF-κB Dependent Genes in SMC
- ICAM1 was used as a marker of NF-κB trans-activating potential in SMC. The rationale for using ICAM-1 relies on its role in promoting accumulation of monocytes and lymphocytes that contribute to the development of atherosclerotic lesions. Up-regulation of ICAM-1 following SMC stimulation was evaluated by Northern blot analysis using specific cDNA probes available in the laboratory. Overexpression of A20 inhibited the up-regulation of ICAM-1 mRNA induction in SMC following TNF treatment as compared to non-infected and rAd.β-gal-infected cells (FIG. 3). These results were confirmed at the protein levels.
- Another NF-κB dependent gene that has been implicated in the development of atherosclerosis is the chemokine monocyte chemottractant protein (MCP)-1 (Ueda et al.,J. of Immunology (1994) 153:2052-2063). MCP-1 not only attracts monocytes to the site of vascular inflammation but has also been implicated in promoting SMC migration and proliferation in the neointima (Streblow et al., Cell (1999) pages 511-520). Like ICAM-1, induction of MCP-1 by pro-inflammatory cytokines is regulated at the transcription level. Up-regulation of MCP-1 following TNF treatment of SMC was therefore evaluated by Northern blot analysis using a human cDNA probe as described (Millan et al., Transplantation (1997) 63:421-429). Over-expression of A20 in SMC inhibited TNF-mediated up-regulation of MCP-1 mRNA as compared to not infected (NI) and rAd.β-gal-infected cells (FIG. 7).
- Overexpression of A20 Inhibits SMC Proliferation Having established that A20 inhibits NF-κB activation, we tested whether such inhibition would affect the rate of SMC proliferation. Activation of NF-κB has been shown to be essential for SMC proliferation (Selzman et al.,Ann. Thorac. Surg. (1999) 67:1227-1232). Cultured human SMC were plated at 50 to 60% confluence in 6 well plates and subsequently cultured in 0.5% FCS medium for 48 hours. SMC were kept in the same medium and infected with rAd.A20, rAd. IκBα (kind gift of Dr. Christopher Wrighton), in addition to A20 to achieve NF-κB inhibition, or the control rAd.β-gal. Twenty-four hours following infection, the medium was replaced with 10% FCS and cells were recovered 24 and 48 h later for cell cycle analysis. DNA content was analyzed by FACScan using Cellquest acquisition software. Analysis of DNA ploidy allows discrimination of cells in G0/G1 versus S versus G2/M phases of the cell cycle. Expression of A20 in SMC inhibited progression of the cells through the cell cycle. SMC expressing A20 are blocked in the G0/G1 phase of the cell cycle: 14.4% of the A20 expressing SMC are in the S+G2/M phases of the cell cycle prior to serum addition. This percentage remains essentially the same at 24 and 48 h (16%) following serum addition (FIG. 4). In contrast, non-infected or rAd.β-gal-infected SMC proliferate in response to serum addition and progress to the S+G2/M phases of the cell cycle. The percentage of SMC in S+G2/M phase of the cell cycle before and after serum addition are noted on FIG. 4. SMC expressing the specific inhibitor of NF-κB, IκBα showed a similar pattern of cell cycle inhibition in response to serum as the one obtained in A20 expressing cells. This latter data confirms that of others showing that NF-κB activation is required for SMC proliferation and is blocked by inhibitors of NF-κB (Autieri et al., Biochem. Bioph. Res. Com. (1995) 213:827-836; Selzman et al., supra). It also suggests that the inhibitory potential of A20 upon SMC proliferation relates to its ability to block NF-κB activation.
- Overexpression of A20 Sensitizes SMC to Cytokine- and Fas-Mediated Apoptosis
- SMC are highly resistant to apoptosis. The molecular basis of this resistance is poorly defined. SMC are readily induced to undergo apoptosis in culture when stimulated with high doses of cytokines including interferon-γ, TNF, and IL-1β, deprived of growth factors, or exposed to oxidized LDL, NO donors or the anti-oxidant pyrrolidine dithiocarbamate (PDTC). We thus tested whether A20, a well accepted anti-apoptotic gene in EC, B cells, and fibroblasts also has this function in SMC. Non-infected, rAd.A20, rAd.β-gal or rAd.IκBα infected SMC were treated with 400 U/ml of rhuTNF, 400 U/ml rhu IFNγ and 100 U/ml of rhu IL-1 β/ml. Forty-eight hours following treatment, cells were harvested, and apoptosis evaluated by DNA content analysis (Ferran et al., supra). Cells with a normal DNA content (>2N) were scored as viable, whereas cells with a hypodiploid DNA content (<2N, termed A0) were scored as apoptotic. Surprisingly, our results revealed that expression of A20 in SMC sensitizes them to cytokine-mediated apoptosis. The percent of apoptotic cells following cytokine treatment increases from 0.3% to 1.6% in non-infected cells, and from 1.2% to 7% in the rAd.β-gal-infected SMC (FIG. 5). In contrast, the percentage of A20-expressing SMC undergoing apoptosis following cytokine treatment increased dramatically and reached 36% at 48 h. Interestingly, expression of IκBα in SMC sensitized the SMC to cytokine-mediated apoptosis, but not to the same extent as A20 despite equivalent inhibition of NF-κB by A20 and IκBα. The percentage of apoptotic SMC expressing IκBα increased from 0.8% to 16% 48 h following cytokine treatment. This data suggests that A20-induced sensitization to cytokine-mediated apoptosis is not solely related to its NF-κB inhibitory activity (FIG. 5).
- Another apoptotic receptor that is expressed on vascular SMC is Fas (CD95) (Chan et al.,Circ. Res. (2000) 86:1038-1046). However and despite Fas expression, many cells including SMC resist Fas-induced apoptosis. Interestingly, medial SMC show a marked heterogeneity to Fas-mediated apoptosis with their sensitivity determined not only by surface expression of Fas but also by differential expression of Fas-signaling proteins below receptor level such as caspase 3 (Chan et al., supra). Interestingly, Fas-mediated apoptosis of smooth muscle cells (SMC) has been suggested as a potential means to inhibit neointima formation (Sata et al., Proc. Natl. Acad. Sci. USA (1998) 95:11213-1217). Fas ligand gene transfer to the vessels inhibits neointima formation. We thus questioned whether A20-mediated sensitization to cytokine-mediated apoptosis would also apply for Fas-mediated apoptosis. Non-infected, rAd.A20 or rAd.β-gal infected SMC were treated with 1 μg/ml anti-Fas antibody IgM clone CH-11 (αFas) (05-201 Upstate or an IgM control antibody in the presence or absence of Actinomyein D (150 nM). Sixteen hours following treatment, cells were harvested, and apoptosis evaluated by DNA content analysis as described earlier. Cells with a normal DNA content (>2N) were scored as viable, whereas cells with a hypodiploid DNA content (<2N, termed A0) were scored as apoptotic. Our results revealed that expression of A20 in SMC sensitizes them to α-Fas-mediated apoptosis. The percent of apoptotic cells following αFas treatment increases from 0.34% to 1.9% in NI cells, and from 0.7% to 2.34% in the rAd.β-gal-infected SMC (FIG. 8). In contrast, the percentage of A20-expressing SMC undergoing apoptosis following cytokine treatment increased dramatically and reached 33% at 16 hours (FIG. 8). Killing was specific for the αFas antibody as control IgM treatment did not modify the percentage of apoptosis in these cells. Interestingly, pretreatment of EC with Actinomycin D did not significantly modify the percentage of αFas-induced apoptosis in SMC whereas it rendered NI and rAd.β-gal infected SMC more prone to apoptosis with the percentage of apoptotic cells reaching the same level as that in A20 expressing SMC (28-35%) (FIG. 8). These results extend the sensitizing function of A20 to apoptosis in SMC to a clearly relevant stimulus within the atherosclerotic lesion i.e. Fas.
- The above-mentioned, rather unexpected, results contrast with the anti-apoptotic function of A20 in EC and other cells. We had previously shown that A20 protects EC from cycloheximide/TNF induced apoptosis and can even overcome IκBα-mediated sensitization of these cells to TNF-induced cell death (Ferran et al., supra).
- Expression of A20 in SMC Inhibits αFAS-Mediated Activation of SMC
- Having shown that A20 sensitizes SMC to αFas-mediated apoptosis, we were concerned about its impact upon the recently described Fas/FADD-mediated activation of inflammatory gene expression in smooth muscle cells. Indeed, Schaub et al have shown that signals initiated by Fas-associated death doman protein (FADD) in SMC induce the expression of chemokines such as MCP-1 and IL-8 and cause massive immigration of macrophages in vivo at the site of atherosclerotic lesions (Schaub et al.,Nature Medicine (2000) 6:790-796). These chemokines are also up-regulated during Fas-induced apoptosis in SMC. Induction of a pro-inflammatory program in SMC during Fas-mediated activation and apoptosis could be deleterious and contribute to the pathogenesis of vascular disease, a side-effect that is clearly undesirable if one is aiming to inhibit atherosclerosis. We therefore checked whether expression of A20 in SMC would, as with the cytokines, inhibit Fas-mediated activation of NF-κB and up-regulation of MCP-1. SMC were either NI or infected with rAd.A20. Forty eight hours following infection, SMC were stimulated with 1 μg/ml of αFas antibody and total RNA was extracted at 0 and 4 hours after stimulation. MCP-1 expression following αFas treatment was analyzed by Northern blot analysis using a human MCP-1 probe. Results confirm that MCP-1 mRNA is up-regulated in
SMC 4 hours following αFas addition. Overexpression of A20 in SMC inhibited αFas-mediated up-regulation of MCP-1 mRNA and also down-regulated the constitutive level detected in NI cells (FIG. 9). - A20-Mediated Sensitization of SMC to Cytokines Is not Associated with a Modification in the Level of the Two Prototypic Anti-Apoptotic BCL Family Members BCL-2 and BCL-XL
- Given the sensitizing effect of A20 expression in SMC upon cytokine and Fas-mediated apoptosis, we questioned whether expression of A20 was modifying the level of expression of Bcl-2 and BCl-XL. SMC were either NI or infected with rAd.A20 and rAd.β-gal as described earlier. Forty eight hours following infection, SMC were stimulated with TNF, IL-1β and IFNγ for 16 hours.
- Cells were then trypsinized washed with PBS and subsequently lysed in RIPA Buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Deoxycolate and 1% SDS) supplemented with protease inhibitors (1 μM of aprotinin and leupeptin, 0.1 μM of TLCK and TPCK and 0.5 μM of PMSF). Protein concentration was measured using Bio-RAD Dc protein assay (Bio-Rad, Hercules, Calif.) and fifteen μg of protein were resolved on reducing sodium dodecyl sulfate (SDS) polyacrylamide gels, transferred onto Immobilon-P membranes (Milipore, Bedford, Mass.) and blocked in Blotto (5% non-fat dry milk in 0.1
% Tween 20 in PBS). Bcl-xS/L and Bcl-2 were detected using 1/500 dilution of an anti Bcl-xS/L rabbit IgG (Santa Cruz) and a 1/1000 dilution of an anti-Bcl-2 mouse IgG1 mAb (Pharmingen, San Diego, Calif.) followed by a 1/3000 dilution of peroxydase-conjugated donkey anti-rabbit or goat anti-mouse secondary antibody (Pierce, Rockford, Ill.) and revealed by enhanced chemiluminescence (NEN, Boston, Mass.). Results indicate that expression of A20 in SMC does not modify the constitutive levels of expression of Bcl-xL nor their levels upon addition of cytokines (FIG. 10). - Establishment of a Mouse Line Expressing A20 in EC
- A transgenic mouse line expressing A20 in EC was established using the Complement (C)1 inhibitor promoter that has been shown to induce specific expression of the transgene in EC (Dr. Mario Tozzi, personal communication). Screening for expression of A20 in EC is currently being performed to establish a line of high expressers. Analysis of A20 expression by means of immunohistochemistry shows specific expression of A20 in EC of the heart (FIG. 6A&B).
- One may determine whether A20 expression is part of the physiological response of the SMC to injury.
- Fourth to sixth passage human aortic SMC monolayer cultures are activated using different agonists that are relevant to the pathogenesis of atherosclerosis. These agonists include TNF, LDL, and oxidized LDL, growth factors (platelet derived growth factor (PDGF)) and CD40 cross-linking. The expression of A20 in SMC following these agonists is evaluated at different time points (1-24 h), both at the mRNA and protein levels as described in the preliminary results. One then tests whether each of these critical mediators of the atherosclerotic lesion will, like TNF, induce the expression of A20. We propose, without limiting the biochemical mechanism of the invention, that A20 induction is part of the “regulatory” response of SMC to injury. Expression of A20 in the SMC may result in the prevention of neointimal hyperplasia. It is presumably only when these regulatory mechanisms are overwhelmed that atherosclerosis develops.
- A20 Overexpression
- One may also test the effect of A20 overexpression via adenoviral-mediated gene transfer in SMC upon (i) NF-κB activation, (ii) up-regulation of NF-κB dependent genes such as ICAM1, inducible nitric oxide synthase (iNOS), microphage chemoattractant factor 1(MCP1) and CD40 (all involved in promoting atherosclerosis) (iii) SMC proliferation and cell cycle regulation. To determine whether the effect of A20 on NF-κB activation is transcription factor specific, one may evaluate whether expression of A20 in SMC affects other transcription factors or signaling pathways involved in SMC proliferation and apoptosis. These include nuclear factor for activated T cells (NF-AT), activated protein-1 (AP-1) and the mitogen-activated protein kinase (MAPK) signaling pathways.
- Mechanisms of Action of A20 in SMC Upon NF-κB Activation
- The central role of NF-κB activation in the development of atherosclerosis is discussed above. The experiments described here are aimed at confirming and extending, to other pro-atherogenic stimuli, our data showing that overexpression of A20 inhibits TNF-mediated NF-κB activation and NF-κB dependent gene expression in SMC. In addition, one may dissect further the level at which A20 interferes within the signaling pathway leading to NF-κB activation.
- SMC cultures overexpressing A20 by means of adenoviral-mediated gene transfer may be activated using oxidized LDL or CD40 cross-linking, two relevant pro-atherogenic stimuli. As discussed above, TNF has already been tested. Whole cells, cytoplasmic and nuclear extracts, and mRNA are harvested at different time points following these treatments and evaluated for (i) expression of the NF-κB dependent genes ICAM-1, VCAM-1, iNOS and CD40, all implicated in the pathogenesis of atherosclerosis; (ii) degradation and phosphorylation of IκBα by means of Western blot analysis; (iii) nuclear translocation of NF-κB by means of EMSA; and (iv) activation of the different kinases (IKKα, IKKβ, NIK and MEKK1) involved in the signaling pathway leading to IκBα phosphorylation (Zandi et al.,Mol. Cell. Biol. (1999) 19:4547-4551). The effect of A20 on these kinases is tested either by means of specific antibodies recognizing the phosphorylated forms of these kinases or by means of in vitro kinase assay evaluating the activity of these kinases on their specific substrates.
- The effect of A20 may also be evaluated on NF-AT and p38 MAP kinase activation to study their potential roles in SMC proliferation and apoptosis (Jing, et al.,Circ. Res. (1999) 84:831-839; Boss et al., J. Biol. Chem. (1998) 273:19664-19671). This study is performed using EMSA and kinase assays. The results obtained with A20 expressing SMC are then compared to those obtained with either non-infected, rAd.β-gal or rAd.IκBα-infected SMC control groups.
- We believe that, as in EC, A20 will act in an agonist independent manner as a broad inhibitor of SMC activation and that this inhibition will occur upstream of IκBα degradation and phosphorylation. One may determine the exact level at which A20 interferes within the kinase cascade leading to NF-κB activation and compare these results with our data obtained in EC. A further delineation of a specific target of A20 in SMC provides data valuable to defining novel therapeutic strategies. These data will also determine to what extent the effect of A20 in SMC is specific to NF-κB or affects other transcription factors or signaling pathways relevant for SMC proliferation and apoptosis.
- The Effect of A20 Expression Upon SMC Proliferation
- SMC proliferation is another marker of NF-κB activation. These experiments test whether by blocking NF-κB activation, A20 will also inhibit SMC proliferation. As described above, SMC cultures are first serum-starved to synchronize their cell cycle within the G0 phase. SMC are then infected with rAd.A20, rAd.IκBα or rAd.β-gal. Entry into the cell cycle and proliferation are then driven by addition of serum or basic fibroblast growth factor (bFGF). Cell cycle progression is then evaluated by means of FACS analysis of DNA content and bromodeoxyuridine incorporation at 24, 48, 60 and 72 h following addition of the growth factors. In addition, cell extracts and mRNA are recovered following the addition of serum to evaluate the effect of A20 expression on cyclin D1, a critical NF-κB-dependent component of the cell cycle. We propose, without limiting the invention, that overexpression of A20 in SMC is likely to be at least as effective as IκBα in inhibiting the proliferation of SMC, with the SMC being retained within the G1 phase of the cell cycle. We believe this effect relates to inhibition of the NF-κB-dependent expression of cyclin D1.
- Impact of A20 Overexpression Upon SMC Apoptosis In Vitro
- Apoptosis is now viewed as beneficial to prevent redevelopment and promote the regression of established atherosclerotic lesions. The present invention demonstrates for the first time that A20 sensitizes SMC to cytokine-mediated apoptosis, making A20 a prime gene therapy target to achieve this aim. These experiments are planned to extend our finding that A20 sensitizes SMC to cytokine-mediated apoptosis and to other apoptotic stimuli that are present within the atherosclerotic plaque i.e. Fas, NO and oxidized LDL. Second, one may determine the molecular basis of the effect of A20 upon the death signaling machinery. These studies evaluate the effect of A20 on activation of caspases, mitochondrial membrane potential, c-myc, cytochrome c release and cleavage of death substrates such as PARP that are the hallmarks of apoptosis.
- As described above, non-infected SMC and SMC infected with rAd.A20, rAd.IκBα or rAd.,β-gal are subjected to 4 different pro-apoptotic stimuli, i.e. a combination of TNF, IL-1 and IFNγ, NO donors, oxidized LDL and Fas cross-linking with anti-Fas antibodies. Apoptosis is assayed at 8, 16, 24 and 48 h following stimulation by means of FACS analysis of DNA content. In addition, cell extracts are recovered at 3, 6, 9, 16 and 24 h to analyze (i) the effect of A20 on the activation of both initiator or class I (caspase 8) and effector or class II (caspase 3,9) caspases using specific colorimetric assays and Western blot analysis, (ii) cytochrome c release in the cytoplasm (iii) c-myc expression and (iv) cleavage of PARP. The effect of A20 on modification of the trans-mitochondrial membrane potential will also be evaluated.
- We have demonstrated that although anti-apoptotic in EC and other cells, A20 functions to sensitize SMC to TNF-mediated apoptosis and can thus contain abnormal cell growth and proliferation. This seems especially true in an inflammatory environment (which induces expression of A20) that is encountered in rejecting allografts and in lesions of atherosclerosis.
- As noted above, this effect relates to more than A20-mediated inhibition of NF-κB, because the sensitizing effect of A20 upon apoptosis is stronger than the one achieved by IκBα despite a similar blockade of NF-κB activation by A20 and IκBα. Evaluating whether A20 has additional effects on other signaling pathways involved in SMC apoptosis such as p38 MAP kinase will further determine the mechanisms by which A20 sensitizes SMC to apoptosis. This novel function of A20 in SMC may indicate specific molecular partners for A20 in SMC. One may identify such specific molecular partners by using a yeast double-hybrid system using A20 as a bait and a SMC cDNA library. These experiments will allow the identification of new partners for A20, in addition to those already described, i.e., TNF receptor-associated factor (TRAF)-1,2 and 6, 14-3-3 and A20 binding inhibitor of NF-κB (ABIN) (Vincenz et al.,J. Biol. Chem. (1996) 271:20029-20034; Heynink et al., FEBS Lett. (1999) 442:147-150; Heyninck et al., J. Cell Biol. (1999) 145:1471-1482; Yeong-Song et al., Proc. Natl. Acad. Sci. USA (1996) 93:6721-6725).
- The Anti-atherogenic Potential of A20 In Vivo
- Both our in vitro and in vivo data provide a rationale for using A20 to counter the development of atherosclerosis. A20 functions in vitro to inhibit SMC activation and proliferation and sensitizes SMC to cytokine-mediated apoptosis. In vivo, A20 expression in SMC of long term surviving heart xenografts and allografts correlates with the absence of atherosclerosis. We propose that A20 has strong anti-atherogenic potential.
- Two different models may be used. First, the well established model of balloon injury of carotid arteries in rabbits (Pollman et al., supra, Guzman et al.,Circulation (1993) 88:2838-2848). This model enables one to study the effect of adenoviral-mediated gene transfer of A20 to the vessel wall (adenoviral-mediated gene transfer to vessels achieves transient but high levels of transgene expression (Guzman et al., supra)) in protecting from intimal hyperplasia, restenosis and atherosclerosis development when the animal are fed a high cholesterol diet.
- Second, one may utilize a transgenic mouse expressing A20 in SMC under the control of one of the newly-developed SMC promoters: the Crp2/SmLim promoter or the smooth muscle heavy chain myosin gene promoter (Madsen et al.,Cire. Res. (1998) 82:908-917,;Yet et al., J. Biol. Chem. (1998) 273:10530-10537). Of course, a variety of promoters known in the art are also suitable for use in this experiment. A20 is cloned under the control of these promoters and the mice are screened for the presence of the transgene by Southern blot analysis and for expression in vessels by immunohistochemistry. These mice are then used as organ donors in models of chronic allograft or xenograft rejection (Hancock et al., supra; Bach et al., Transpl. Proc. (1997) 29:56-58).
- Additionally, these mice may be crossed with mice expressing A20 in EC to test whether expression of A20 is required in both EC and SMC to inhibit TAV. Mice expressing A20 in their SMC or in their SMC and EC are then crossed with already established lines of atherosclerosis prone mice (i.e., the LDL receptor knock out or the ApoE deficient mice), to evaluate whether A20 will protect these animals from the development of atherosclerotic lesions (Breslow,Science (1996) 272:685-688). Two transgenic mouse lines that may be used are the LDL-receptor deficient mice available through the Jackson Laboratory and the APO E deficient mice (Plump et al., Cell (1992) 71:343-352; Ishibashi et al., J. Clin. Invest. (1994) 93:1885-1893). The evaluation of the anatomical lesions and their correlation with the expression of the transgene may be performed by immunohistochemistry.
- We predict that gene transfer of A20 to the vessel wall will inhibit intimal proliferation and restenosis in the rabbit balloon injury model. Based upon this, clinical therapies using adenoviral or lentiviral vectors may be developed (Morsy et al.,Proc. Natl. Acad. Sci. (1998) 95:7866-7871; Amado et al., Science (1999) 285:674-676). Generation of mice expressing A20 in SMC may be done to confirm the protective function of A20 when expressed in SMC (and EC) in protecting from TAV. Conditional expression of the transgene under the control of the tetracycline operon may be needed to circumvent these potential results. Such constructs are publicly available (Gossen et al., Proc. Natl. Acad. Sci. USA (1992) 89:5547-5551).
- Recombinant constructs are well known in the art, (see, Maniatis et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y.). Methods of producing transgenic mammals using recombinant constructs are well known and include, but not limited to, microinjection, embryonic stem (ES) cell manipulation, electroporation, cell gun, transfection, transduction, retroviral infection, etc. Species of constructs may be introduced individually or in groups of two or more types of constructs.
- According to one preferred embodiment of the invention, a transgenic pig may be produced that expresses a SMC specific pro-apoptotic factor (e.g., A20). Briefly, estrus may be synchronized in sexually mature gilts (>7 months of age) by feeding an orally active progestogen (allyl trenbolone, AT: 15 mg/gilt/day) for 12 to 14 days. On the last day of AT feeding all gilts may be given an intramuscular injection (IM) of prostaglandin F2a (Lutalyse: 10 mg/injection) at 0800 and 1600 hours. Twenty-four hours after the last day of AT consumption all donor gilts may be administered a single IM injection of pregnant mare serum gonadotropin (PMSG: 1500 IU). Human chorionic gonadotropin (HCG: 750 IU) may be administered to all donors at 80 hours after PMSG.
- Following AT withdrawal, donor and recipient gilts may be checked twice daily for signs of estrus using a mature boar. Donors that exhibit estrus within 36 hours following HCG administration may be bred at 12 and 24 hours after the onset of estrus using artificial and natural (respectively) insemination.
- Between 59 and 66 hours after the administration of HCG one- and two-cell ova may be surgically recovered from bred donors using the following procedure. General anesthesia may be induced by administering 0.5 mg of acepromazine/kg of body weight and 1.3 mg ketamine/kg of body weight via a peripheral ear vein. Following anesthetization, the reproductive tract may be exteriorized following a mid-ventral laparotomy. A drawn glass cannula (O.D. 5 mm,
length 8 cm) may be inserted into the ostium of the oviduct and anchored to the infundibulum using a single silk (2-0) suture. Ova may be flushed in retrograde fashion by inserting a 20 g needle into the lumen of theoviduct 2 cm anterior to the uterotubal junction. Sterile Dulbecco's phosphate buffered saline (PBS) supplemented with 0.4% bovine serum albumin (BSA) may be infused into the oviduct and flushed toward the glass cannula. The medium may be collected into sterile 17×100 mm polystyrene tubes. Flushings may be transferred to 10×60 mm petri dishes and searched at low power (50×) using a Wild M3 stereomicroscope. All one- and two-cell ova may be washed twice in Brinster's Modified Ova Culture-3 medium (BMOC-3) supplemented with 1.5% BSA and transferred to 50 μl drops of BMOC-3 medium under oil. Ova may be stored at 38° C. under a 90% N2, 5% O2, 5% CO2 atmosphere until microinjection is performed. - One- and two-cell ova may be placed in an Eppendorf tube (15 ova per tube) containing 1 ml HEPES Medium supplemented with 1.5% BSA and centrifuged for 6 minutes at 14000×g in order to visualize pronuclei in one-cell and nuclei in two-cell ova. Ova may then be transferred to a 5-10 μl drop of HEPES medium under oil on a depression slide. Microinjection may be performed using a Laborlux microscope with Nomarski optics and two Leitz micromanipulators and 10-1700 copies of construct DNA (linearized at a concentration of about 1 ng/μl of Tris-EDTA buffer) may be injected into one pronuclei in one-cell ova or both nuclei in two-cell ova.
- Microinjected ova may be returned to microdrops of BMOC-3 medium under oil and maintained at 38° C. under a 90% N2, 5% CO2, 5% O2 atmosphere prior to their transfer to suitable recipients. Ova may preferably be transferred within 10 hours of recovery.
- Only recipients which exhibit estrus on the same day or 24 hours later than the donors may preferably be utilized for embryo transfer. Recipients may be anesthetized as described earlier. Following exteriorization of one oviduct, at least 30 injected one-and/or two-cell ova and 4-6 control ova may be transferred in the following manner. The tubing from a 21 g×¾ butterfly infusion set may be connected to a 1 cc syringe. The ova and 1-2 mls of BMOC-3 medium may be aspirated into the tubing. The tubing may then be fed through the ostium of the oviduct until the tip reaches the lower third or isthmus of the oviduct. The ova may be subsequently expelled as the tubing is slowly withdrawn.
- The exposed portion of the reproductive tract may be bathed in a sterile 10% glycerol-0.9% saline solution and returned to the body cavity. The connective tissue encompassing the linea alba, the fat, and the skin may be sutured as three separate layers. An uninterrupted Halstead stitch may be used to close the linea alba. The fat and skin may be closed using a simple continuous and mattress stitch, respectively. A topical antibacterial agent (e.g. Furazolidone) may then be administered to the incision area.
- Recipients may be penned in groups of about four and fed 1.8 kg of a standard 16% crude protein corn-soybean pelleted ration. Beginning on day 18 (
day 0=onset of estrus), all recipients may be checked daily for signs of estrus using a mature boar. On day 35, pregnancy detection may be performed using ultrasound. On day 107 of gestation recipients may be transferred to the farrowing suite. In order to ensure attendance at farrowing time, farrowing may be induced by the administration of prostaglandin F2a (10 mg/injection) at 0800 and 1400 hours on day 112 of gestation. In all cases, recipients may be expected to farrow within 34 hours following PGF2a administration. - Twenty-four hours after birth, all piglets may be processed, i.e. ears notched, needle teeth clipped, 1 cc of iron dextran administered, etc. A tail biopsy and blood may also be obtained from each pig.
- For additional methods for making transgenic pigs see, Pinckert et al.,Xeno, Vol. 2, No. 1, 1994, incorporated herein by reference. One skilled in the art would, of course, know how to modify these methods from the exact protocols disclosed herein.
- The results above demonstrate a novel function for A20 in SMC: inhibition of SMC proliferation and sensitization to apoptosis. This later function contrasts with the cytoprotective effect of A20 in EC and makes A20 a unique gene therapy tool to protect the vessels from the development of atherosclerosis. Indeed, the conventional paradigm emphasizes the critical role of EC activation and SMC proliferation as two culprits of atherosclerotic lesion progression. The present invention provides evidence that A20 can function to inhibit both of these deleterious components, in part based on the pro-apoptotic effects of A20 in SMC.
- The cellular and molecular biology methods that we intend to use in the experiments described above are well known in the art. This includes experimental models of mouse transplantation. The balloon injury model will be carried out under the guidance of surgeons expert in the technique within the NIH-funded Harvard-Longwood Research Training in Vascular Surgery, with which we are associated.
- All references cited herein are hereby incorporated by reference in their entirety.
Claims (56)
1. A method of treating or preventing vascular disease comprising modifying a mammalian smooth muscle cell by inserting into said smooth muscle cell, or a progenitor thereof, DNA encoding a protein capable of decreasing inflammation and increasing apoptosis of said smooth muscle cell and transplanting said smooth muscle cell, or a tissue or organ comprising such a cell, into a transplant candidate or a patient diagnosed with a vascular disease, wherein said protein has A20 activity.
2. The method of , wherein said vascular disease comprises atherosclerosis, transplant-associated vasculopathy, or chronic rejection.
claim 1
3. A method of treating or preventing transplant-associated vasculopathy (TAV) comprising modifying a mammalian smooth muscle cell by inserting into said smooth muscle cell, or a progenitor thereof, DNA encoding a protein capable of decreasing inflammation and increasing apoptosis of said smooth muscle cell and transplanting said smooth muscle cell, or a tissue or organ comprising such a cell into a patient at risk for developing TAV, wherein said protein has A20 activity.
4. The method of or , wherein said protein is A20.
claim 1
3
5. The method of or , wherein said protein further blocks smooth muscle cell proliferation.
claim 1
3
6. The method of , wherein said A20 comprises a mutant or derivative of said A20.
claim 4
7. A method of treating atherosclerosis comprising transplanting donor smooth muscle cells, or graftable tissues or organs comprising smooth muscle cells, to a mammalian recipient having atherosclerosis or a vascularized organ transplant, comprising the steps of (a) modifying the donor smooth muscle cells, or progenitor smooth muscle cells thereof, by inserting therein DNA encoding A20; and (b) transplanting the resultant modified donor smooth muscle cells, or tissues or organ comprising the cells into the recipient, and expressing in the cells A20, thereby substantially promoting apoptosis.
8. A method of preventing TAV comprising, transplanting donor smooth muscle cells, or graftable tissues or organs comprising smooth muscle cells, to a mammalian recipient comprising the steps of (a) modifying the donor smooth muscle cells, or progenitor smooth muscle cells thereof, by inserting therein DNA encoding A20; and (b) transplanting the resultant modified donor smooth muscle cells, or tissues or organ comprising the cells into the recipient, and expressing in the cells A20, thereby substantially promoting apoptosis in the presence of a cellular activating stimulus.
9. The method of or , wherein said method substantially inhibits inflammation in the presence of a cellular activating stimulus.
claim 7
8
10. The method of or , wherein said A20 comprises a mutant or derivatives of A20.
claim 7
8
11. A method of preparing a vascularized organ or vessel for transplantation into a patient comprising obtaining an organ or vessel for transplant and perfusing said organ or vessel with nucleic acid encoding A20 protein.
12. The method of , wherein said nucleic acid encoding A20 is inserted within a vector comprising an adenovirus vector or a lentivirus vector.
claim 11
13. The method of , further comprising perfusing said organ or vessel with an immunoregulatory factor.
claim 11
14. The method of , wherein said immunoregulatory factor is a cytokine.
claim 13
15. The method of , wherein said immunoregulatory factor is Fas.
claim 13
16. The method of , wherein said perfusing occurs in vivo.
claim 13
17. The method of , wherein said perfusing occurs ex vivo.
claim 13
18. The method of , wherein said A20 comprises a mutant or derivative of said A20.
claim 12
19. The method of , further comprising enhancing the expression of A20 using a therapeutic agent.
claim 11
20. The method of , wherein said patient has suffered ischemia, reperfusion injury, mechanical injury, immunologic injury, pharmacologic injury, or coronary trauma.
claim 11
21. The method of , wherein said patient has undergone balloon angioplasty.
claim 11
22. The method of , wherein said patient has atherosclerosis.
claim 11
23. The method of , wherein said organ or vessel is being prepared as a vascularized organ or a vascular graft.
claim 11
24. A mammalian smooth muscle cell which is modified to express A20, said A20 being capable of inhibiting inflammation and promoting apoptosis in the presence of a cellular activating stimulus, said modified smooth muscle cell exhibiting increased sensitivity to apoptosis, relative to an untreated smooth muscle cell.
25. The smooth muscle cell of , wherein said A20 further blocks smooth muscle cell proliferation.
claim 24
26. The smooth muscle cell of , wherein said A20 comprises a mutant or derivative of A20.
claim 24
27. A donor smooth muscle cell, or a tissue or organ comprising such a cell, for transplantation into a recipient species, wherein said cell is modified to express A20, said A20 being capable of inhibiting inflammation and promoting apoptosis in the presence of a cellular activating stimulus in said recipient.
28. The smooth muscle cell of , wherein said A20 further blocks smooth muscle cell proliferation.
claim 27
29. The smooth muscle cell of , wherein said A20 comprises a mutant or derivative of A20.
claim 27
30. An organ or vessel from a non-human transgenic or somatic recombinant mammal comprising DNA encoding a pro-apoptotic protein of a different species, wherein said protein has A20 activity.
31. An organ or vessel according to which is porcine.
claim 30
32. An organ or vessel according to , wherein said pro-apoptotic protein is human.
claim 30
33. A method of identifying compounds that substantially promote apoptosis and substantially inhibit growth or proliferation in smooth muscle cells comprising,
a) exposing smooth muscle cells to a compound; and
b) measuring activation of A20 in smooth muscle cells.
34. A method of identifying compounds that substantially promote apoptosis and substantially inhibit growth or proliferation in smooth muscle cells comprising,
a) exposing smooth muscle cells to a compound; and
b) measuring binding of said compound to a pro-apoptotic protein, wherein said protein is A20.
35. A method of treating a patient having a vascularized organ transplant, a vessel transplant, or vascular disease comprising enhancing A20 biological activity.
36. A method of preventing vascular disease in a patient comprising enhancing A20 biological activity.
37. The method of or , wherein said method comprises administering to said patient a therapeutic agent.
claim 35
36
38. The method of , wherein said therapeutic agent comprises a cytokine.
claim 37
39. The method of , wherein said therapeutic agent comprises Fas.
claim 37
40. The method of , wherein said therapeutic agent comprises a drug.
claim 37
41. A method of promoting apoptosis in smooth muscle cells in a patient, said method comprising increasing the level of A20 in said smooth muscle cells.
42. The method of , wherein said smooth muscle cell is engineered to express A20.
claim 41
43. The method of or , wherein said A20 protein comprises a mutant or derivative of said A20 protein.
claim 36
42
44. The method of , wherein said method comprises administering to said patient a therapeutic agent.
claim 41
45. The method of , wherein said therapeutic agent comprises a transcription factor.
claim 44
46. The method of , wherein said therapeutic agent comprises a cytokine.
claim 44
47. The method of , wherein said therapeutic agent comprises a drug.
claim 44
48. The method of , wherein said therapeutic agent comprises Fas.
claim 44
49. The method of , wherein said patient has a vascularized organ transplant, a vessel transplant, or vascular disease.
claim 41
50. The method of , wherein said vascularized organ comprises the heart, liver, or kidney.
claim 49
51. The method of , wherein said vascular disease comprises atherosclerosis or TAV.
claim 49
52. A method of inducing cell death of undesired proliferating smooth muscle cells within the neointima of a diseased vessel, said method comprising, enhancing A20 biological activity in said smooth muscle cell.
53. A method of inducing cell death of undesired proliferating smooth muscle cells within the neointima of a diseased vessel, said method comprising, increasing the level of A20 in said smooth muscle cell.
54. The method of or , wherein said method comprises administering to said smooth muscle cell a therapeutic agent.
claim 52
53
55. A method of treating or preventing vascular disease in a patient comprising, preparing a smooth muscle cell, or tissue or organ comprising a smooth muscle cell, for transplant by treating said smooth muscle cell, or tissue or organ comprising a smooth muscle cell, with a therapeutic agent that increases A20 biological activity in said smooth muscle cell, or tissue or organ comprising said smooth muscle cell, and transplanting said smooth muscle cell, or tissue or organ comprising said smooth muscle cell, treated with said therapeutic agent to a patient at risk for developing vascular disease.
56. A method of treating or preventing vascular disease in a patient comprising preparing a smooth muscle cell, or tissue or an organ comprising a smooth muscle cell, for transplant by treating said smooth muscle cell, or tissue, or organ comprising a smooth muscle cell, with a therapeutic agent that increases the A20 level in said smooth muscle cell, or tissue or organ comprising said smooth muscle cell, and transplanting said smooth muscle cell, or tissue or organ comprising said smooth muscle cell, treated with said therapeutic agent to a patient at risk for developing vascular disease.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/765,519 US20010053769A1 (en) | 2000-01-21 | 2001-01-19 | Use of pro-apoptotic factors in treatment of atherosclerosis |
US10/461,200 US7297685B2 (en) | 2000-01-21 | 2003-06-13 | Use of pro-apoptotic factors in treatment of atherosclerosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17753500P | 2000-01-21 | 2000-01-21 | |
US09/765,519 US20010053769A1 (en) | 2000-01-21 | 2001-01-19 | Use of pro-apoptotic factors in treatment of atherosclerosis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/461,200 Continuation US7297685B2 (en) | 2000-01-21 | 2003-06-13 | Use of pro-apoptotic factors in treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010053769A1 true US20010053769A1 (en) | 2001-12-20 |
Family
ID=22648970
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/765,519 Abandoned US20010053769A1 (en) | 2000-01-21 | 2001-01-19 | Use of pro-apoptotic factors in treatment of atherosclerosis |
US10/461,200 Expired - Fee Related US7297685B2 (en) | 2000-01-21 | 2003-06-13 | Use of pro-apoptotic factors in treatment of atherosclerosis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/461,200 Expired - Fee Related US7297685B2 (en) | 2000-01-21 | 2003-06-13 | Use of pro-apoptotic factors in treatment of atherosclerosis |
Country Status (3)
Country | Link |
---|---|
US (2) | US20010053769A1 (en) |
AU (1) | AU2001231009A1 (en) |
WO (1) | WO2001052639A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171253A1 (en) * | 2001-04-19 | 2003-09-11 | Averil Ma | Methods and compositions relating to modulation of A20 |
US20080274102A1 (en) * | 2003-10-07 | 2008-11-06 | Yeda Research And Development Co., Ltd | Antibodies to Nik, Their Preparation and Use |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009009587A2 (en) * | 2007-07-09 | 2009-01-15 | Board Of Regents Of The University Of Nebraska | Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5015568A (en) | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
JPH04507041A (en) | 1988-12-13 | 1992-12-10 | アメリカ合衆国 | Endothelial cells modified by genetic engineering and methods for their use |
JP3249516B2 (en) | 1990-10-31 | 2002-01-21 | ソマティクス セラピー コーポレイション | Retroviral vectors for gene therapy |
EP0670737A4 (en) | 1992-03-26 | 1996-05-29 | Gensia Inc | In vivo peptide therapy. |
GB9222931D0 (en) | 1992-11-02 | 1992-12-16 | Sandoz Ltd | Organic compounds |
US5550019A (en) | 1993-05-26 | 1996-08-27 | La Jolla Cancer Research Foundation | Methods of identifying compounds which alter apoptosis |
US5646008A (en) | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
ES2256843T3 (en) | 1993-11-30 | 2006-07-16 | Tanox, Inc. | PROTEINS WITH WHICH THEY MODULATE APOPTOSIS, CODANT DNA FOR THESE PROTEINS, AND THEIR MODE OF USE. |
CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
US5571523A (en) | 1995-03-09 | 1996-11-05 | President And Fellows Of Harvard College | Antioxidant-induced apoptosis in vascular smooth muscle cells |
EP0886650A1 (en) | 1996-02-14 | 1998-12-30 | Novartis AG | Gene therapy of entothelial cells with anti-apoptotic proteins for transplantation and inflammatory conditions |
US5776905A (en) | 1996-08-08 | 1998-07-07 | The Board Of Trustees Of The Leland Stamford Junior University | Apoptotic regression of intimal vascular lesions |
AU1306899A (en) * | 1997-11-07 | 1999-05-31 | Board Of Trustees Of The Leland Stanford Junior University | Mammalian pro-apoptotic bok genes and their uses |
-
2001
- 2001-01-19 US US09/765,519 patent/US20010053769A1/en not_active Abandoned
- 2001-01-19 AU AU2001231009A patent/AU2001231009A1/en not_active Abandoned
- 2001-01-19 WO PCT/US2001/001894 patent/WO2001052639A1/en active Application Filing
-
2003
- 2003-06-13 US US10/461,200 patent/US7297685B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171253A1 (en) * | 2001-04-19 | 2003-09-11 | Averil Ma | Methods and compositions relating to modulation of A20 |
US20080274102A1 (en) * | 2003-10-07 | 2008-11-06 | Yeda Research And Development Co., Ltd | Antibodies to Nik, Their Preparation and Use |
Also Published As
Publication number | Publication date |
---|---|
US7297685B2 (en) | 2007-11-20 |
AU2001231009A1 (en) | 2001-07-31 |
WO2001052639A1 (en) | 2001-07-26 |
US20030207838A1 (en) | 2003-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100793220B1 (en) | Quiescent cell populations for nuclear transfer | |
Zhang et al. | Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies | |
Oropeza et al. | Transgenic expression of the human A20 gene in cloned pigs provides protection against apoptotic and inflammatory stimuli | |
CN103275980B (en) | Antibody, fusion rotein and composition | |
EP1519957B1 (en) | Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair | |
KR20010105331A (en) | Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses | |
US5786341A (en) | Use of a COL1A1 mini-gene construct to inhibit collagen synthesis | |
JP2001511650A (en) | Methods for regulating hematopoiesis and angiogenesis | |
Moscioni et al. | Long-term correction of albumin levels in the Nagase analbuminemic rat: repopulation of the liver by transplanted normal hepatocytes under a regeneration response | |
Zhang et al. | Cardiomyocytes induce macrophage receptor shedding to suppress phagocytosis | |
US20070238663A1 (en) | Use of HMGB1 to promote stem cell migration and/or proliferation | |
KR100958291B1 (en) | A Method for treatment of anxiety disorder by regulating T?type calcium channel | |
US7297685B2 (en) | Use of pro-apoptotic factors in treatment of atherosclerosis | |
HU228978B1 (en) | Use of long pentraxin ptx3 for treating female infertility | |
Hernández-Gutierrez et al. | NF-κB signaling blockade by Bay 11-7085 during early cardiac morphogenesis induces alterations of the outflow tract in chicken heart | |
CN115381949A (en) | Application of targeted inhibition of pigment epithelium derived factor in promotion of liver regeneration and improvement of liver injury | |
JP2001502527A (en) | Methods for inhibiting smooth muscle cell proliferation | |
Tian et al. | An HSV-TK transgenic mouse model to evaluate elimination of fibroblasts for fibrosis therapy | |
Carey et al. | Regulation of Expression and Phosphorylation of A9/aß Integrin in Normal and Neoplastic Keratinocytes¹ | |
WO1997012040A1 (en) | GENE THERAPY WITH MODIFIED p65 PROTEINS | |
Elbert | MATERNAL IMMUNITY: PREIMPLANTATION PREPARATION AND SPATIAL DISTRIBUTION OF CCL19 | |
Liliensiek | Investigation into the role of the defender against apoptotic death protein (DAD1) in keratinocyte differentiation and survival | |
Han | Role of inducible genes in axon regeneration in mammalian spinal motoneurons | |
Camp | Macrophage clearance of cell death during mouse embryogenesis | |
Coles | Programmed cell death in the developing kidney and the ubiquity of the programme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, MASSACHUSETT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FERRAN, CHRISTIANE;ARVELO, MARIA B.;REEL/FRAME:011723/0388 Effective date: 20010216 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |